Document:

EX-10.18

 Exhibit 10.18 

CONFIDENTIALTREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

EXCLUSIVE LICENSE AGREEMENT 

This Exclusive License Agreement (this “Agreement”) is made as of this
19th day of July, 1999 (the “Effective Date”) by and between Introgen Therapeutics, Inc., a Texas corporation having its principal place of business at 301 Congress Avenue, Suite
1850, Austin, Texas 78701 (“Introgen”), Corixa Corporation, a Delaware corporation having its principal place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104 (the “Company”), and Chinook
Corporation, a Delaware corporation and a wholly-owned subsidiary of the Company (“Chinook,” and, collectively with the Company, “Corixa”). 

RECITALS 
 A.
GenQuest, Inc., a Delaware corporation (“GenQuest”), and Introgen entered into a Special Biological Materials Transfer and Collaboration Agreement dated February 4, 1998 (the “Prior Agreement”), pursuant to
which GenQuest granted to Introgen (i) an exclusive license to use the Licensed Technology (as defined below) to conduct the research set forth on Schedule 1 to the Prior Agreement (the “Research”) upon the terms and subject to
the conditions of the Prior Agreement and (ii) an option to obtain an exclusive license to the Licensed Technology as described in the Prior Agreement (the “Option”). 

B. Effective September 15, 1998, GenQuest was acquired by Corixa by merger with and into Chinook Corporation, which is wholly owned by
Corixa and was the surviving entity in such merger. 
 C. In satisfaction of the Option, Introgen desires to obtain, and Corixa is willing
to grant to Introgen, an exclusive license to the Licensed Technology, including the results of the Research, upon the terms and subject to the conditions of this Agreement. 

NOW, THEREFORE, in consideration of the promises and the mutual covenants herein set forth, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows: 
 1. DEFINITIONS 

In addition to the terms defined elsewhere in this Agreement, the following words and phrases, whenever capitalized in this Agreement, shall
have the following meanings: 
 1.1 “Affiliate” shall mean, with respect to a party, any entity that controls, is
controlled by, or is under common control of a party. For this purpose, control of an entity shall mean direct or indirect ownership of fifty percent (50%) or more of the voting interest in, or a fifty percent (50%) or greater interest in
the equity of, such corporation or other business entity, or the maximum percentage allowed by law in the country of the controlled entity. 

 1.2 “Annual Net Sales” shall mean, in each calendar year during the term of this
Agreement, the gross amounts received by Introgen or its Affiliates in the case of sales by Introgen or its Affiliates to Third Parties (or to Affiliates that are end users), or the gross amounts received by sublicensees of Introgen or its
Affiliates in the case of sales by such sublicensees to Third Parties (or to Affiliates that are end users), for sales of Licensed Products to Third Parties (or to Affiliates that are end users) less the following amounts: (a) normal customary
trade, quantity, cash and other discounts allowed and actually taken; (b) allowances for credits granted for returns, rebates and the like; (c) sales, use, value added and similar taxes and duties paid; and (d) packaging and handling
fees and prepaid shipping, freight and insurance. For the removal of doubt, Annual Net Sales shall not include sales by Introgen to its Affiliates for resale, provided that if Introgen sells a Licensed Product to an Affiliate for resale, Annual Net
Sales shall include the amounts received by such Affiliate to Third Parties on the resale of such Licensed Product. Notwithstanding the foregoing, Annual Net Sales shall not include amounts received in consideration of a transfer or sale of
reasonable quantities of Licensed Products for use in research and development or in clinical trials. 
 1.3 “Combination
Product” shall mean any subject matter, including, but not limited to, products and processes, containing both a component that constitutes a Licensed Product and one or more devices or active components that would not alone constitute
Licensed Products. 
 1.4 “Fair Market Value,” with respect to equity securities, shall mean a price per share of not
greater than [***] ([***]%) of, (a) if such securities are traded on a securities exchange or The Nasdaq Stock Market, the average of the closing prices over the ten (10) trading days preceding the date of calculation, (b) if such
securities are actively traded over-the-counter, the average of the closing bid or sales price (whichever is applicable) over the ten (10) trading days preceding the date of calculation and (c) if such securities are not so traded, the
fair market value as determined in good faith by the Board of Directors of the issuer, with due consideration given to the potential earnings, business and prospects of such issuer and the price at which other equity securities of the issuer have
been issued. 
 1.5 “Field” shall mean all gene therapy applications in humans, including without limitation therapeutic,
prophylactic and diagnostic applications relating to gene therapy. Notwithstanding the foregoing, the Field shall not include any administration of the Licensed Gene or Gene Products in any formulation for the primary purpose of eliciting a
prophylactic or therapeutic immune response directed to the Licensed Gene or Gene Products or one or more epitopes contained therein. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 2 

 1.6 “Gene Products” shall mean any and all peptide(s) and protein(s) encoded by
the Licensed Gene, any derivatives of such peptide(s) and protein(s), and antibodies to such protein(s) and derivatives. 

  
 3 

 1.7 “Licensed Gene” shall mean the MDA-7 gene and any fragments or derivatives
thereof, as and to the extent covered by the Licensed Patents. 
 1.8 “Licensed Know-How” shall mean any and all technical
information, processes, compositions, formulae, data, engineering, materials, reports, analyses, know-how, trade secrets and other subject matter owned and/or controlled by Corixa relating directly and specifically to the Licensed Gene and that is
reasonably necessary for the development, manufacture and/or commercialization of the Licensed Products in the Field. 
 1.9
“Licensed Patents” shall mean any and all rights owned and/or controlled by Corixa in and to: 
 (a) all worldwide patents
and patent applications owned or controlled by Corixa or its Affiliates claiming or disclosing the subject matter claimed or disclosed in those patent applications listed on Exhibit 1.9 hereto or in any foreign counterpart of the
foregoing; 
 (b) all worldwide patents and patent applications claiming or disclosing inventions owned or controlled by Corixa or its
Affiliates relating to the MDA-7 gene of any fragment or derivatives thereof that are made prior to the second anniversary of the Effective Date; and 

(c) all divisions, continuations, continuations-in-part, foreign counterparts, patents of addition, and substitutions of, and all patents
issuing on, any of the foregoing patents, together with all registrations, reissues, reexaminations or extensions of any kind with respect to any of the foregoing patents. 

1.10 “Licensed Technology” shall mean, collectively, (a) the Licensed Gene, (b) the Licensed Patents and
(c) the Licensed Know-How. 
 1.11 “Licensed Products” shall mean any product, composition or material the
manufacture, sale or use of which would, but for the license granted herein, infringe a Valid Claim in the country for which such product, composition or material is sold. 

1.12 “Major Indication” shall mean any indication in humans for which the parties mutually agree that at least five thousand
(5,000) patients exist in the United States. 
 1.13 “Major Market” shall mean any one of the following: (a) the
United States, (b) Europe, which for purposes of this Agreement shall mean any of Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Spain, Sweden, Switzerland and the United Kingdom or
(c) Japan. 
 1.14 “Market Launch” shall mean the date on which Introgen or an Affiliate in the case of sales by
Introgen or its Affiliates to Third Parties (or to an Affiliate that is an end-user) or a sublicensee of Introgen or any of its Affiliates in the case of sales by such sublicensee to Third Parties (or to an Affiliate that is an end-user), first
transfers title to or otherwise sells a Licensed 

  
 4 

 
Product to a Third Party in exchange for revenue. The transfer of a reasonable amount of Licensed Products intended for clinical use or for research or other non-commercial use shall not be
included in the calculation of the date of Market Launch. 
 1.15 “Net Licensing Proceeds” shall mean the license fees
received by Introgen from a sublicensee in consideration of a sublicense under the Licensed Technology, including up-front license fees, sublicense fees and technology access fees, and all milestone payments
so received, less (i) any applicable withholding taxes and any other amounts credited or deducted against the amounts actually received by Introgen, unless and until Introgen recoups such taxes or charges through a credit against taxes due or
against other cash payments that Introgen otherwise would be required to make, and (ii) any amounts paid to a Third Party (including without limitation the Fair Market Value as of the date of issuance of any equity issued to such Third Party to
the extent that such equity is issued as a license fee and is not purchased for other consideration by such Third Party) with respect to the license, sublicense or acquisition of additional intellectual property rights and relating to a Licensed
Product covered by such sublicense agreement. Net Licensing Proceeds shall not include (a) any equity or amounts received as payment for equity securities (up to the Fair Market Value of such securities as of the date of issuance), (b) any
amounts received in direct connection with the sale or provision of products or materials or services or (c) any amounts received in consideration of bona fide research or development activities. For the avoidance of doubt, it is understood
that in no event shall Net Licensing Proceeds be deemed to include Annual Net Sales, running royalties or any amount other than cash payments expressly included above in this Section 1.15; nor shall Net Licensing Proceeds be deemed to include
amounts received in consideration for a sale of all or substantially all of the business or assets of Introgen to which this Agreement pertains (whether by way of merger, sale of stock, sale of assets or otherwise) or in connection with any other
transaction resulting in an assignment of this Agreement in accordance with Section 13.3. 
 1.16 “Regulatory
Authority” shall mean the U.S. Food and Drug Administration or its foreign equivalent. 
 1.17 “Third Party” shall
mean a party other than Introgen, Corixa or either of their Affiliates. 
 1.18 “Valid Claim” shall mean a claim of an
issued and unexpired patent or a claim of a pending patent application within the Joint Patents or the Licensed Patents which has not been held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction
and has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise; provided, however, that if the holding of such court or agency is later reversed by a court or agency with overriding
authority, the claim shall be reinstated as a Valid Claim with respect to Annual Net Sales made after the date of such reversal. 
 1.19
“Singular and Plural”. Where the context hereto requires, the singular number shall be deemed to include the plural and vice versa. 

  
 5 

 2. LICENSE GRANT; SUMMARY DATA 

2.1 Exclusive License. Corixa hereby grants to Introgen an exclusive, worldwide license, with the right to sublicense under the Licensed
Technology solely to research, make, have made, use, sell, offer to sell, have sold, import and otherwise distribute Licensed Products, practice any method, process or procedure, or otherwise exploit the Licensed Technology; provided that such
license shall in each case be limited to the Field (the “Exclusive License”). 
 2.2 Sublicensing. Introgen may
grant and authorize sublicenses within the scope of the Exclusive License. Introgen shall keep Corixa reasonably informed as to its progress in entering into sublicense agreements. Each such sublicense agreement shall comply with the terms and
conditions of this Agreement. 
 2.3 Summary Data. During the term of this Agreement, Introgen will supply Corixa with summary data
pertaining to research, development and uses of the Licensed Technology, including, without limitation, the Licensed Products, in the Field. The type and frequency of the disclosure of such summary data shall be mutually agreed upon by the parties.
Such summary data shall be considered Confidential Information of Introgen under Section 8 of this Agreement. 
 2.4 Supply of
Materials. Upon reasonable request by Introgen and in consideration for the research and development payments set forth in Section 4.3, Corixa shall provide reasonable quantities of the materials, reagents and other items within the
Licensed Technology listed on Exhibit A attached hereto. Such reagents shall be delivered subject to the Terms and Conditions of Purchase and Supply of Reagents attached hereto as Exhibit B. 

2.5 Notwithstanding any provision in this Agreement to the contrary, Corixa shall not assert against Introgen or a Licensed Product any patent
now or hereafter obtained or controlled by Corixa or its Affiliate, solely to the extent that such patent claims cover the Licensed Gene or Gene Products, or the use or production thereof. 

3. DUE DILIGENCE; RESEARCH PROGRAM 

3.1 Due Diligence. Introgen shall use diligent efforts (itself or through others) to achieve the following milestones for the Licensed
Products within the specified number of months after the Effective Date: 
  

			
	 Event
	  	Months After the
Effective Date
	(a) Acquisition or development of non-viral gene therapy technology (“Non-Viral Technology”), either internally or through a funded collaboration with a Third Party, reasonably sufficient to enable Introgen to
deliver Licensed Technology for cancer therapy.	  	3

  
 6 

					
	(b) Completion of testing for efficacy in an animal model using Non-Viral Technology.	  	 	15	  
		
	(c) Commencement of Phase I Clinical Trial of a Licensed Product for a Major Indication.	  	 	15	  
		
	(d) Completion of Phase I Clinical Trial of a Licensed Product for a Major Indication.	  	 	26	  
		
	(e) Completion of Phase II Clinical Trial of a Licensed Product for a Major Indication.	  	 	41	  
		
	(f) Completion of Phase III Clinical Trial of a Licensed Product for a Major Indication.	  	 	61	  

 With respect to Introgen’s obligations under events (a) and (b) above, the parties acknowledge that,
notwithstanding Introgen’s use of diligent efforts, Introgen may not achieve the event described therein. In such event, so long as Introgen is conducting research or development activities (directly or through others) with respect to Non-Viral
Technology or using diligent efforts to seek to acquire Non-Viral Technology to achieve the milestones in (a) and (b) above, Introgen shall not be considered in breach of same by reason of its failure to achieve such milestones. In
addition, in any event, the sole remedy for any breach by Introgen of its obligations with respect to (a) and (b) above, shall be that the Exclusive License granted hereunder shall be converted to a non-exclusive license with respect to
the delivery of the Licensed Genes by means of a delivery system that does not involve viral vectors or viral particles. In the event that Corixa shall be obligated or shall elect to make any payments to Columbia as set forth in Section 6(b) of
the Amended and Restated Research and License Agreement (the “Columbia Agreement”) dated July 18, 1997 by and between GenQuest and The Trustees of Columbia University in the City of New York (“Columbia”) and as amended by
Paragraph 3 of Amendment No. 1 to the Columbia Agreement dated March 5, 1999 (including, without limitation, Appendix C) for failure to achieve, or to extend, its due diligence milestones thereunder, Introgen shall reimburse Corixa for
[***] ([***]%) of such payments at the time Corixa is obligated to make such payment to Columbia. 
 3.2 Research Program. 

(a) During the term of the Research Program (as set forth below), the parties shall collaborate with respect to a research program, as
described on Exhibit C attached hereto (the “Research Program”). The Research Program may be amended from time to time by mutual agreement of the parties, and any such revised Research Program shall be set forth in
writing and attached hereto as Exhibit C. No material deviation in the subject matter or scope of the Research Program shall be made without the mutual written agreement of both parties. The term of the Research Program shall commence on
the Effective Date and terminate on the second anniversary of the Effective Date, subject to extension on mutually agreeable terms and conditions 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 7 

 (b) by agreement of the parties; provided, however, that the Research Program
shall terminate effective upon any termination of this Agreement in accordance with Section 9. 
 (c) Corixa shall keep Introgen
reasonably informed as to the progress and results of the Research Program, including without limitation, submitting to Introgen biannual written reports within thirty (30) days of the end of each calendar half year summarizing the research and
results obtained therefrom during the prior six (6) month period relating to the research in connection with the Research Program. Without limiting the foregoing, Corixa shall promptly notify Introgen in writing of all discoveries and
inventions developed during the Research Program and, with respect to such discoveries or inventions, either file a patent application at Introgen’s expense in accordance with Article 12 below or authorize and cooperate fully to permit Introgen
to do so. It is understood and agreed that Corixa shall expend the funds paid to Corixa by Introgen under Section 4.3 solely to conduct the Research Program, subject to Section 9.4 below. 

4. FEES AND PAYMENTS 

4.1 License Fee. In consideration of the Exclusive License, within five (5) days of the Effective Date Introgen shall pay to Corixa
a one-time fee of [***] ($[***]). 
 4.2 Initial Research and Development Payment. In consideration of the research and development
services performed by Corixa prior to the Effective Date, within five (5) days of the Effective Date Introgen shall pay to Corixa a one-time fee of [***] ($[***]). 

4.3 Future Research and Development Payments. In consideration of the research and development services to be performed by Corixa under
the Research Program, Introgen shall pay to Corixa eight (8) payments in the amount of [***] ($[***]), the first of which shall be due and payable within five (5) days of the Effective Date and the remainder of which shall be due and
payable at the end of each three-month period thereafter. 
 4.4 Milestones; Net Licensing Proceeds; Payments. 

(a) In further consideration of the Exclusive License, Introgen shall make the following milestone payments to Corixa with respect to the
first Licensed Product to meet the corresponding milestone event specified below: 
 (i) [***] ($[***]) within thirty (30) days
following the successful completion by Introgen of the first Phase I Clinical Trial for such Licensed Product for the first Major Indication that is a human cancer; 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 8 

 (ii) [***] ($[***]) within thirty (30) days following the successful completion by Introgen
of the first Phase I Clinical Trial for a Licensed Product for the first Major Indication that is not a human cancer; 
 (iii) [***]
($[***]) within thirty (30) days following the successful completion by Introgen of the first Phase III Clinical Trial for such Licensed Product for the first Major Indication that is a human cancer; 

(iv) [***] ($[***]) within thirty (30) days following the successful completion by Introgen of the first Phase III Clinical Trial for a
Licensed Product for the first Major Indication that is not a human cancer; 
 (v) [***] ($[***]) within thirty (30) days following
the first approval in the United States by the U.S. FDA of such Licensed Product for the first Major Indication that is a human cancer; 

(vi) [***] ($[***]) within thirty (30) days following the first approval in Europe or Japan by a Regulatory Authority of a Licensed
Product for the first Major Indication that is a human cancer; 
 (vii) [***] ($[***]) within thirty (30) days following the first
approval in a Major Market by a Regulatory Authority of a Licensed Product for the first Major Indication that is not a human cancer; and 

(viii) [***] ($[***]) within thirty (30) days following the first approval in a Major Market by a Regulatory Authority of a Licensed
Product for an additional Major Indication that is a human cancer (each, an “Additional Major Indication”). It is understood that payments under this Section 4.2(a)(viii) shall be due for no more than three (3) Additional
Major Indications, and, accordingly, the total amount due under this Section 4.2(a)(viii) shall not exceed [***] ($[***]). 
 For
purposes of this Section 4.4, “successful completion” shall be deemed to occur, with respect to a particular clinical trial for a Licensed Product, upon the earlier of (i) the dosing of all patients to be treated in such clinical
trial, and completion in all material respects of any monitoring period, as described in the protocol for such trial, and the completion of a summary report of such trial by the principal investigator, or (ii) initiation of a later phase
clinical trial for the same Licensed Product. It is understood that, except as noted in milestone (viii) above, each of the foregoing milestone payments shall be due only once and that, accordingly, the total amount to be paid under this
Section 4.4(a) shall not exceed [***] ($[***]). 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 9 

 (b) Introgen shall pay to Corixa [***] ([***]%) of all Net Licensing Proceeds; but in no event
shall the aggregate cumulative amount paid under this Section 4.4(b) exceed [***] ($[***]). Payment of such amounts shall be made in accordance with Section 5.1 hereof. Any amounts paid or owing to Corixa under Section 4.4(a) above
with respect to a milestone event shall be deducted as a credit against any payments due under this Section 4.4(b) following the date such milestone event was achieved (it being understood that for purposes of this Section 4.4(b) only, the
milestone event shall be deemed achieved upon the occurrence of the event described in (i)-(viii) of Section 4.4(a), without the lapse of the thirty (30) day period following such event in which the
payment under Section 4.4(a) becomes due (i.e., for example, for purposes of this Section 4.4(b), the milestone event described in Section 4.4(a)(i) shall be deemed to have occurred upon the successful completion of such Phase
I clinical trial, and not the lapse of thirty (30) days following such completion). 
 4.5 Royalties. 

(a) Introgen shall pay to Corixa a royalty equal to the following percentages of Annual Net Sales: 

 

					
	 Annual Net Sales
	  	Percentage of Annual Net Sales
to be Paid to Corixa	 
	 First $250,000,000
	  	 	4.5	% 
	 Annual Net Sales in excess of $250,000,000
	  	 	5	% 

 (b) In the event that Annual Net Sales are at least One Hundred Million Dollars ($100,000,000) in the first
twelve (12) months following Market Launch, then Introgen shall pay to Corixa a one-time bonus payment of One Million Dollars ($1,000,000), payable along with the royalty payment for the fourth quarter of such year in accordance with
Section 5.1. 
 4.6 Credit. Introgen shall receive a credit against royalties payable to Corixa pursuant to Section 4.5 on
a quarterly, country-by-country basis in the amount of any royalty payments or license fees made or required to be made to Third Parties by Introgen, its Affiliates or sublicensees in connection with the development, use, manufacture or sale of
Licensed Products to the extent such payment obligation(s) are paid for the right to practice patent rights that cover any portion of the coding region of the Licensed Gene that codes for any portion of the Gene Product; provided,
however, that the royalties that would otherwise be due to Corixa may not be reduced pursuant to this Section 4.6 by more than [***] ([***]%) in any quarter. It is understood that for such purposes “cover” shall include
covering the composition or use of the particular portion of the coding region of the Licensed Gene that codes for any portion of the Gene Product. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 10 

 4.7 Single Royalty; Non-Royalty Sales. In the event that more than one Valid Claim(s)
within the Licensed Patents is applicable to any Licensed Product subject to royalties under this Section 4, then only one royalty shall be paid to Corixa in respect of such Licensed Product. It is understood that royalties shall only be
payable under this Section 4 with respect to sales of Licensed Products that would, but for the license granted hereunder, infringe a Valid Claim in the country in which such Licensed Product is sold or manufactured. In no event shall more than
one royalty be due hereunder with respect to any Licensed Product unit. 
 4.8 Combination Products. For purposes of calculating the
amounts due under this Section 4 for Combination Products, Annual Net Sales shall be reasonably allocated between such Licensed Product and the device or active component(s) of such Combination Product that do not constitute Licensed Products
based upon their relative importance and proprietary protection and the gross selling price of such device or active component(s) sold separately; provided, however, that in no event shall less than [***] ([***]%) of the Annual
Net Sales of a Combination Product be allocated to the Licensed Product. Similarly, in the event that a Combination Product is sublicensed without a separate license fee, then, for purposes of determining Net Licensing Proceeds, the license fees
paid for the Combination Product shall be reasonably allocated between the Licensed Product and such other subject matter; provided, however, that in no event shall less than [***] ([***]%) of the Net Licensing Proceeds of a
Combination Product be allocated to the Licensed Product. 
 5. PAYMENTS AND REPORTS 

5.1 Payments and Reports. The payments required pursuant to Sections 4.4(b) and 4.5 shall be paid on a quarterly basis, and shall
be due and payable within forty-five (45) days after the last day of March, June, September and December of each year. All amounts past due shall bear interest at an [***] ([***]%) from the date they are due until the date they are paid. Each
such payment shall be accompanied by a statement, in sufficient detail describing the Annual Net Sales invoiced, Net Licensing Proceeds received, the Licensed Products sold, the amount of Licensed Product sold and the basis for calculating the
accrued royalties. All information provided by Introgen pursuant to this Section 5.1 shall be deemed Confidential Information of Introgen. 

5.2 Calculation of Payment. The calculation of the payments required hereunder shall be based on Annual Net Sales and Net Licensing
Proceeds in U.S. Dollars. Annual Net Sales or Net Licensing Proceeds paid in any foreign currency shall be converted into and paid on the basis of an average rate of exchange, which shall be computed as the rate of exchange quoted under Foreign
Exchange in The Wall Street Journal (U.S. West Coast edition) for the last business day of the calendar quarter to which such payment pertains. If at any time legal restrictions in a particular country prevent the prompt remittance of any
amounts from such jurisdiction, Introgen may make such payments with respect to such jurisdiction by depositing the amount thereof in local currency in a bank account or other depository in such country in the name of Corixa, and Introgen shall have
no further obligations under this Agreement with respect thereto. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 11 

 5.3 Payment of Applicable Taxes. Each party shall bear and pay any and all taxes, duties,
levies, and other similar charges (and any related interests and penalties), however designated, imposed on that party as a result of the existence or operation of this Agreement. 

5.4 Records. Introgen shall keep full, complete and proper records and accounts of Annual Net Sales and Net Licensing Proceeds. Upon
reasonable notice to Introgen, Corixa shall have the right to have an independent certified public accountant, selected by Corixa and acceptable to Introgen, audit Introgen’s records pertaining to the Licensed Products during normal business
hours to verify the amounts payable pursuant to this Agreement; provided, however, that: (a) such audit shall not take place more frequently than once each calendar year, and (b) shall not cover such records for more than the preceding
three (3) years. The independent certified public accountant will be obliged to execute a reasonable confidentiality agreement prior to commencing any such inspection. Such audit shall be at Corixa’s expense unless Introgen has paid Corixa
less than [***] ([***]%) of the amount determined to be due for the time period covered by such audit, in which case such audit shall be at Introgen’s expense. Introgen shall preserve and maintain all such records and accounts required for
audit for a period of at least three (3) years after the quarter to which such records and accounts apply. 
 6. OWNERSHIP OF
INTELLECTUAL PROPERTY 
 6.1 Acknowledgement. The parties hereby acknowledge that except as expressly set forth herein, neither
party shall receive any right, title or interest to any proprietary rights or intellectual property rights of the other party. 
 6.2
Corixa Inventions. All inventions, discoveries and improvements (“Inventions”) related to the Licensed Technology, whether or not patentable, made solely by employees or others acting on behalf of Corixa during the term of
this Agreement (“Corixa Inventions”) shall be owned solely and exclusively by Corixa. For purposes of this Article 6, an Invention shall be deemed “made” by an individual if such individual would be the inventor
thereof under applicable patent law (or the author or creator thereof under applicable intellectual property law, for non-patentable inventions). 

6.3 Introgen Inventions. All Inventions related to the Licensed Products or based in whole or in part upon any Licensed Technology in
the Field, whether or not patentable, made solely by employees or others acting on behalf of Introgen during the term of this Agreement (“Introgen Inventions”) shall be owned solely and exclusively by Introgen. 

6.4 Joint Inventions and Joint Patents. 

(a) Joint Inventions. All Inventions related to Licensed Technology in the Field, whether or not patentable, made jointly by employees
or others acting on behalf of Introgen 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 12 

 
and Corixa during the term of this Agreement (“Joint Inventions”), shall be jointly owned by Introgen and Corixa under United States federal laws pertaining to joint ownership of
inventions. All of Corixa’s right, title and interest in the Joint Inventions (other than Corixa’s right, title and interest in the Joint Patents, as defined below) shall be considered part of Licensed Know-How. Each party shall promptly
disclose in writing the existence of Joint Inventions to the other party. 
 (b) Joint Patents; License Grant. All patents and
patent applications covering Joint Inventions, including without limitation all patents and/or patent applications arising during or after the term of this Agreement which claim the priority of any patent and/or patent application claiming and
disclosing Joint Inventions (“Joint Patents”), shall be jointly owned by Introgen and Corixa under United States federal laws pertaining to joint ownership of patents. Corixa hereby grants to Introgen an exclusive, worldwide
license, with right of sublicense, to all of Corixa’s right, title and interest in the Joint Patents, to develop, make, have made, use, sell, have sold, import and otherwise distribute Licensed Products within the Field. Introgen shall have the
first right, but not the obligation, to prosecute and reasonably maintain the Joint Patents to effectively cover discoveries and inventions relating to the Field. All costs and expenses incurred in such prosecution will be borne by Introgen. In the
event that Introgen decides not to continue the prosecution or maintenance of any Joint Patent in general or in any particular country, Introgen will promptly notify Corixa in writing in reasonably sufficient time for Corixa to assume such
prosecution or maintenance, and Introgen will take the necessary steps and execute the necessary documents to permit Corixa to assume such prosecution or maintenance. Corixa will have the right but not the obligation to assume such prosecution or
maintenance at its own expense. At the request of the party performing the prosecution of any patent application under this Section 6.4(b), the other party will cooperate, in all reasonable ways, in connection with the prosecution and
maintenance of all such patent applications. Each party will make available to the other party or its respective authorized attorneys, agents or representatives such of its employees as the other party in its reasonable judgment deems necessary in
order to assist such other party with the prosecution and maintenance of such patents. Each party will sign or use its best efforts to have signed at no charge to the other party all legal documents necessary in connection with such prosecution and
maintenance. Upon request, each party shall advise the other promptly of any action or development in the prosecution of Joint Patents, including without limitation those involving the question of scope or the issuance of, the rejection of, an
interference involving, or an opposition to any such patent application or patent. Additionally, each party shall provide the other party copies of all such patents and draft patent applications to be filed by such party on Joint Inventions, and the
other party shall have the opportunity to review all such pending applications and other proceedings and make recommendations to the filing party concerning them and their conduct. 

7. PATENT INFRINGEMENT AND ENFORCEMENT 

7.1 Defense. If the development, manufacture, sale or use of any Licensed Product within the Field pursuant to this Agreement results in
a claim, suit or proceeding alleging patent infringement against Introgen, its Affiliates or any of its or any of its Affiliates’ suppliers, sublicensees, distributors, or customers (collectively, “Actions”), Introgen shall
promptly notify Corixa and send Corixa copies of all papers that have been served, to the extent Introgen has the right to do so. As between the parties to this Agreement, Introgen shall be entitled to control the defense of such Action and Corixa
shall, and Corixa shall cause its Affiliates to, at all times cooperate with Introgen. In the event of any such Action relating to the portion of the coding region 

  
 13 

 
of the Licensed Gene that codes for any portion of the Gene Product, Introgen shall have the right to withhold one-half (1/2) of the amounts otherwise payable to Corixa under Article 4 with
respect to the Licensed Products that are the subject of such Action, and use the withheld amounts to reimburse up to one (1/2) of the legal defense costs, attorneys’ fees and liability incurred in such Actions. Notwithstanding the
foregoing, Introgen agrees to withhold only that portion of such amounts as may be reasonably necessary to reimburse amounts in accordance with this Section 7.1. If Introgen is required to pay a royalty to a Third Party to make and/or sell a
Licensed Product as a result of a final judgment or settlement, such amounts may be deducted from the running royalties payable to Corixa hereunder in relation to such Licensed Product; provided that the royalties otherwise due to Corixa under
Section 4.3 shall not be so reduced by more than [***] ([***]%). 
 7.2 Infringement. If during the term of this Agreement,
either party becomes aware of a third party infringement or threatened infringement of any Licensed Patents, the following provisions shall apply: 

(a) Introgen shall have the right, but not the obligation, to bring suit (itself or through a designee) to enforce the Licensed Patents,
and/or to defend any declaratory judgment action with respect thereto, in each case with respect to the manufacture, sale or use of a product within the Field; provided, however, that Introgen shall keep Corixa reasonably informed as to the defense
and/or settlement of such action. Corixa shall have the right to participate in any such action with counsel of its own choice at its own expense. Without limiting the provisions of Section 7.3 below, Corixa agrees to cooperate with Introgen
with respect to actions brought by Introgen under this Section 7.2(a) at Introgen’s request and expense. If Introgen decides to undertake such suit, then any amounts received by Introgen in such Action with respect to infringement that
occurred prior to the judgment awarding such amounts shall be included, after deducting the costs incurred by Introgen in connection with such Action, in Annual Net Sales hereunder. 

(b) If Introgen elects not to so initiate an action to enforce the Licensed Patents against a commercially significant infringement by a
Third Party within the Field, within one hundred eighty (180) days of a request by Corixa to do so, Corixa may initiate such action at its expense; provided, however, that Corixa shall keep Introgen reasonably informed as to the
defense and/or settlement of such action, as requested from time to time by Introgen, and provided that there is not then ongoing a litigation in any country with respect to the Licensed Technology. Introgen shall have the right to participate in
any such action with counsel of its own choice at its own expense. Introgen agrees to cooperate with Corixa with respect to actions brought by Corixa under this Section 7.2(b) at Corixa’s request and expense. If Corixa undertakes such
suit, then, after deducting the costs incurred by Corixa in connection with such Action, Introgen shall be entitled to receive [***] ([***]%) of any amounts received by Corixa in such action. 

(c) Upon Introgen’s reasonable request, Corixa agrees to use reasonable efforts, including, but not limited to, with respect to the
exercise of rights under the Columbia Agreement (as defined in Section 10.1) to cause Columbia (as defined in Section 10.1) to cooperate in any suit, action or other proceeding under this Section 7.2, at Introgen’s expense. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 14 

 7.3 Cooperation. In any suit, action or other proceeding in connection with enforcement
and/or defense of the Licensed Patents, the party not bringing such suit, action or proceeding shall cooperate fully, at the other party’s expense, including without limitation by joining as a party plaintiff and executing such documents as the
other party may reasonably request. Upon the request of and at the expense of the party bringing such suit, the other party shall use reasonable efforts to make available at reasonable times and under appropriate conditions all relevant personnel,
records, papers, information, samples, specimens and other similar materials in such party’s possession. 
 7.4 Settlement.
Neither party shall be permitted to settle a legal action, to the extent such settlement expressly admits that the Licensed Patents are invalid, without the consent of the other party, which consent shall not be unreasonably withheld. 

8. CONFIDENTIALITY 

8.1 Definition of Confidential Information. It is contemplated that in the course of the performance of this Agreement each party may,
from time to time, disclose proprietary and confidential information to the other (“Confidential Information”). Confidential Information shall include all disclosures made hereunder or under previous confidentiality agreements
between the Parties in writing and identified as being “Confidential,” or if disclosed orally, which are reduced to writing within thirty (30) days of oral disclosure and clearly identified as being “Confidential.” Introgen
and Corixa agree that this Agreement shall supersede all previous confidentiality agreements between the parties and all disclosures made under any previous confidentiality agreements shall be subject to the terms of this Section 8. 

8.2 Nondisclosure of Confidential Information. Except to the extent expressly authorized by this Agreement or otherwise agreed to in
writing, during the term of this Agreement and for a period of five (5) years following the termination of this Agreement, each party shall take such reasonable measures to protect the secrecy of and avoid disclosure or use of such Confidential
Information of the other party in order to prevent it from falling into the public domain or the possession or person other than those persons authorized under this Agreement to have any such information. Such measures shall include, but not be
limited to, the highest degree of care the receiving party takes to protect its own proprietary and confidential information of a similar nature, which shall be no less than reasonable care. Neither party shall disclose or permit disclosure of any
Confidential Information of the other party to third parties or to employees of the party receiving Confidential Information, other than directors, officers, employees, consultants and agents who are required to have the information in order to
carry out the terms of this Agreement and who are bound by appropriate confidentiality restrictions. Each party shall notify the other in writing of any actual or suspected misuse, misappropriation or unauthorized disclosure of the other
party’s Confidential Information that may come to such party’s attention. 
 8.3 Exceptions. The following information
shall not be considered Confidential Information: 

  
 15 

 (a) information which was already known to the receiving party, other than under an obligation
of confidentiality to the disclosing party, at the time of disclosure by the other party; 
 (b) information which was generally available
to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; 
 (c) information which becomes
generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this Agreement; 

(d) information which was disclosed to the receiving party, other than under an obligation of confidentiality, by a third party who had no
obligation to the disclosing party not to disclose such information; or 
 (e) information which was developed independently without
reference to Confidential Information received from the other party hereunder as evidenced by the receiving party’s own written records. 

8.4 Permitted Usage. Notwithstanding the provisions of Section 8.1 above, the receiving party may use or disclose Confidential
Information of the disclosing party in connection with the exercise of its rights hereunder (including commercialization and/or sublicensing) or the fulfillment of its obligations and/or duties hereunder and in filing for, prosecuting or maintaining
any proprietary rights, prosecuting or defending litigation, complying with applicable governmental regulations and/or submitting information to tax or other governmental authorities; provided that if the receiving party is required by law to make
any public disclosures of Confidential Information of the disclosing party, to the extent it may legally do so, it shall give reasonable advance notice to the disclosing party of such disclosure and shall use its reasonable efforts to secure
confidential treatment of Confidential Information prior to its disclosure (whether through protective orders or otherwise). 
 9.
TERM/TERMINATION 
 9.1 Term and Expiration. Unless earlier terminated pursuant to this Article 9 the term of this Agreement
shall expire upon the expiration of the last to expire patent of the Licensed Patents. Sections 2.1 and 2.2 shall, with respect to the Licensed Know-How, survive the expiration (but not an earlier termination) of this Agreement. 

9.2 Termination For Material Breach. In the event of a material breach of this Agreement, the nonbreaching party shall be entitled to
terminate this Agreement by written notice to the breaching party, if such breach is not cured within ninety (90) days after written notice is given by the nonbreaching party to the breaching party specifying the breach. However, if the party
alleged to be in breach of this Agreement disputes such breach within such ninety (90) day period, the nonbreaching party shall not have the right to terminate this Agreement unless it has been determined in accordance with Section 13.9
below that this Agreement was materially breached, and the breaching party fails to comply with its obligations hereunder within ninety (90) days after such determination. 

  
 16 

 9.3 Termination for Insolvency. Either party may terminate this Agreement upon written
notice to the other in the event of (a) the appointment, by a court of competent jurisdiction, of a receiver for all or any substantial part of the other party’s properties, provided that such receiver is not discharged within sixty
(60) days of its appointment; (b) the adjudication of the other party as bankrupt; or (c) the execution by the other party of an assignment of substantially all of its assets for the benefit of its creditors. 

9.4 Termination Upon Notice. Any provision herein notwithstanding, Introgen may terminate this Agreement, in its entirety, as to any
particular patent or patent application within the Licensed Patents or as to any particular Licensed Product, at any time by giving Corixa written notice thereof. From and after the effective date of a termination under this Section 9.4 with
respect to a particular patent or application, such patent(s) and patent application(s) in the particular country shall cease to be within the Licensed Patents for all purposes of this Agreement, and all rights and obligations of Introgen with
respect to such patent(s) and patent application(s) shall terminate. From and after the effective date of a termination under this Section 9.4 with respect to a particular Licensed Product, the Exclusive License shall terminate with respect to
such Licensed Product, and the same shall cease to be a Licensed Product for all purposes of this Agreement. Upon a termination of this Agreement in its entirety under this Section 9.4, (a) all rights and obligations of the parties shall
terminate, except as provided in Section 9.9 below and (b) all payments set forth in Sections 4.1, 4.2 and 4.3 shall accelerate and shall be due and payable to Corixa on the effective date of such termination. 

9.5 Consequences of Early Termination. If this Agreement is terminated pursuant to Section 9.2 above, each party shall return or
destroy, and certify to such destruction of, all Confidential Information of the other party, except that each party may maintain one (1) copy for archival purposes solely to confirm compliance with the provisions of Section 8. 

9.6 Survival of Sublicenses. Upon termination of this Agreement for any reason, any sublicense granted by Introgen hereunder shall
survive; provided that, upon request by Corixa, such sublicensee agrees in writing to be bound by all the applicable terms and conditions of this Agreement. 

9.7 Inclusive Remedy. Except as otherwise provided in this Agreement, each party shall have the rights and remedies set forth herein in
addition to any other remedies which it may have under applicable statutory or common law. Each party shall have the sole discretion to determine which of its rights and remedies, if any, it shall pursue and such party shall not be required to
exhaust any of its other rights or remedies before pursuing any one of the rights and remedies set forth in this Agreement. 
 9.8
Inventory. Upon any termination of this Agreement, Corixa hereby grants Introgen a license to sell, or otherwise dispose of, any of Introgen’s or its Affiliates’ inventories of Licensed Products in process of manufacture, in use or
in stock that have not previously been sold on the date of such termination, provided that Introgen shall make all applicable royalty or other payments on such sales pursuant to Section 4 above. 

  
 17 

 9.9 Survival. Expiration or early termination of this Agreement shall not relieve either
party of its obligations for payments that were due or accrued prior to expiration or early termination, included, but not limited to, any payments due or accrued. In addition, the provisions of Sections 1, 6, 8, 9, 10, 11 and 13 shall survive any
expiration or early termination of this Agreement. 
 10. REPRESENTATIONS AND WARRANTIES 

10.1 By Introgen. Introgen represents and warrants to Corixa that (a) Introgen has full right and authority to enter into this
Agreement, and that this Agreement is a valid and binding obligation of Introgen enforceable in accordance with its terms, and (b) Introgen shall use its best commercial efforts to ensure that all of the Licensed Products manufactured by it or
on its behalf comply with all relevant legislation in force from time to time in each country where the Licensed Products are manufactured or sold, including but not limited to the requirements of any relevant Regulatory Authority or legislation
requiring that the Licensed Products be manufactured in accordance with current good manufacturing practices. Introgen acknowledges that the Exclusive License includes sublicenses under technology that has been licensed to Corixa pursuant to the
Columbia Agreement, and Introgen represents, warrants and covenants that it will comply with Section 12 of the Columbia Agreement. 

10.2 By Corixa. Corixa warrants and represents to Introgen that: (a) it has and will maintain the full right and authority to
enter into this Agreement and grant the rights and licenses granted herein, subject to the provisions of the Columbia Agreement; (b) it has not previously granted and will not grant any rights or licenses in conflict with the rights and
licenses granted herein; (c) to its knowledge, no action, suit or claim has been initiated or threatened with respect to the Licensed Technology that would call into question Corixa’s right to enter into and perform its obligations under
this Agreement; (d) Corixa has provided to Introgen true, correct and complete copies of the Columbia Agreement, except for the redaction of financial terms that do not affect Introgen’s rights or obligations hereunder; (e) the
Columbia Agreement is in full force and effect as of the Effective Date and grants to Corixa the right and power to grant the rights and licenses granted to Introgen herein, subject to Introgen’s obligation pursuant to Section 10.1 to
comply with all applicable terms and conditions of the Columbia Agreement; (f) to Corixa’s knowledge, neither Corixa, nor Columbia is in breach of any provision of the Columbia Agreement, and Corixa has neither given to, nor received from,
Columbia notice of any such breach and there is no dispute pending that relates to the Columbia Agreement; (g) as of the Effective Date, except for those patents and patent applications set forth on Exhibit 1.9 (including any
foreign counterparts of such patent applications and patents and all divisions, continuations, continuations-in-part, patents of addition, substitutions, registrations, reissues, reexaminations or extensions
of any kind with respect to any of the foregoing), neither Corixa nor any of its Affiliates control any patent or patent application claiming or disclosing inventions relating to the Licensed Gene or the Gene Products or that would reasonably be
expected to cover the commercialization of a product within the Field incorporating the Licensed Gene; and (h) to Corixa’s knowledge as of the Effective Date, except as set forth on Exhibit 10.2 attached hereto, the practice of
the Licensed Patents within the Field will not infringe any intellectual property right of a third party, and Exhibit 10.2 lists all patents and patent 

  
 18 

 
applications of which, as of the Effective Date, Corixa is aware that Corixa expects to have a direct material adverse effect on Introgen’s ability to commercialize a product within the
Field incorporating the Licensed Gene; and (i) as of the Effective Date, Corixa is not aware of any reason that would reasonably be expected to preclude the issuance as a valid patent the pending claims of patent applications within the
Licensed Patents, or that would reasonably be expected to render invalid or unenforceable any claims of an issued patent within the Licensed Patents. 

10.3 Extent of Warranties. EXCEPT AS SPECIFICALLY PROVIDED IN THIS AGREEMENT, NEITHER CORIXA NOR INTROGEN MAKES ANY WARRANTIES OF ANY
KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

11. INDEMNIFICATION 

11.1 Indemnification by Corixa. Corixa shall defend, indemnify and hold Introgen and its directors, officers and employees harmless from
and against any and all liabilities, damages, losses, costs or expenses (including legal fees) resulting from claims, actions, suits or proceedings brought by third parties arising out of or resulting from Corixa’s (a) material breach of
its obligations hereunder, (b) breach of its representations and warranties set forth in Section 10.2 above or (c) gross negligence or willful misconduct. 

11.2 Indemnification by Introgen. Introgen shall defend, indemnify and hold Corixa and Columbia and their respective directors,
officers and employees harmless from and against any and all liabilities, damages, losses, costs or expenses (including legal fees) resulting from claims, actions, suits or proceedings brought by third parties arising out of or resulting from
Introgen’s (a) material breach of its obligations hereunder, (b) breach of its representations and warranties set forth in Section 10.1 above, (c) gross negligence or willful misconduct, (d) manufacture, packaging, use,
sale, rental or lease of Licensed Products by or under the authority of Introgen, even if altered for use for a purpose not intended, or (e) use of the Licensed Technology by or under the authority of Introgen. 

11.3 Conditions of Indemnification. The agreements of indemnity set forth in Sections 10.1 and 10.2 above are conditioned upon the
indemnified party’s obligation to: (i) advise the indemnifying party of any claim or suit, in writing, within sixty (60) days after the indemnified party has received notice of such claim or suit, and (ii) assist the indemnifying
party and its representatives in the investigation and defense of any claim and/or suit for which indemnification is provided. This agreement of indemnity shall not be valid as to any settlement of a claim or suit or offer of settlement or
compromise without the prior written approval of the indemnifying party. 
 11.4 Insurance. No later than the initiation of the first
clinical trial for a Licensed Product and continuing during the term of this Agreement and for five (5) years thereafter, Introgen shall, at its sole cost and expense, obtain and keep in force a policy of comprehensive general liability
insurance with bodily injury, death and property damage limits of Two Million Dollars ($2,000,000) per occurrence and Three Million Dollars ($3,000,000) in the aggregate, including product liability coverage and such additional provisions or
coverage as is reasonable and customary 

  
 19 

 
under the circumstances. Such insurance shall include Corixa and Columbia and their respective trustees, directors, officers, employees and agents as additional insureds, and shall provide that
the insurer will give Corixa not less than thirty (30) days advance notice of any material change in or cancellation of coverage. At Corixa’s request, Introgen shall furnish a certificate of insurance evidencing the insurance required
hereunder. 
 11.5 No Consequential Damages. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO
THE OTHER WITH RESPECT TO THE SUBJECT MATTER OF THE AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR (A) ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL OR INDIRECT DAMAGES WHATSOEVER, (B) COST OF
PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES OR (C) LOSS OF PROFIT OR ANTICIPATED BUSINESS. 
 12. PATENT
PROSECUTION; PAYMENT OF PATENT EXPENSES 
 12.1 Prosecution and Payment. The parties acknowledge and agree that all patent
applications relating to the Licensed Technology will be prepared, filed and prosecuted by Columbia upon the terms and subject to the conditions of the Columbia Agreement. All costs incurred by Corixa prior to the Effective Date with respect to the
Licensed Patents are the sole responsibility of Corixa, and all costs incurred by Corixa during the term of this Agreement pursuant to the Columbia Agreement with respect to the reimbursement of patent expenses incurred by Columbia are the sole
responsibility of Introgen to the extent such Licensed Patents pertain to the Field. To the extent that Corixa has the right to prosecute Licensed Patents within the Field under the Columbia Agreement or otherwise and Corixa reasonably elects to do
so (which election Corixa shall not withhold unreasonably if Introgen so requests), Introgen shall bear all expenses incurred in connection therewith. In any event, Corixa agrees to keep Introgen fully informed on a timely basis with respect to the
prosecution and maintenance, and any proceedings (including without limitation any interference or opposition proceedings, or the like) with respect to, the Licensed Patents. Notwithstanding the foregoing, Introgen shall be responsible for all costs
incurred by Corixa from the Effective Date through August 20, 1999 on Licensed Patents in Exhibit 1.9 to the extent necessary to effect the filing of divisionals and continuations within the Field during such time. 

12.2 Additional Licenses. In the event that Corixa shall license the Licensed Technology to any Third Parties outside of the Field,
Introgen’s obligation to bear all of the post-Effective Date patent expenses pursuant to Section 12.1 shall be reduced on a pro rata basis based upon the number of such Third Party licensees (i.e., to fifty percent (50%) if one
(1) such Third Party licensee, or to thirty-three and one-third percent (33 1/3%) if two (2) such Third Party licensees. 

  
 20 

 13. MISCELLANEOUS 

13.1 Notices. All notices, requests or other communications required or permitted to be given under this Agreement to any party shall be
in writing and shall be deemed to have been sufficiently given when delivered by personal service or sent by registered mail, telex or facsimile, to the recipient addressed as follows: 

	 	(a)	If to Corixa: 

 Corixa Corporation 

1124 Columbia Street 

Suite 200 

Seattle, WA 98104 

Facsimile: (206) 754-5762 

Attention: President 

                 Director of Legal
Affairs 
  

	 	With	a copy to: 

 William W. Ericson 

Venture Law Group 

4750 Carillon Point 

Kirkland, WA 98033 

Facsimile: (425) 739-8750 
  

	 	(b)	If to Introgen: 

 Introgen Therapeutics, Inc. 

301 Congress Avenue 

Suite 1850 

Austin, TX 78701 

Facsimile: (512) 320-4166 

Attn: Vice President, Corporate Development 
  

	 	With	a copy to: 

 Wilson Sonsini Goodrich & Rosati 

650 Page Mill Road 

Palo Alto, CA 94304 

Attn: Kenneth A. Clark 

Facsimile: (650) 493-6811 

All such communications shall be deemed to be effective on the day on which personally served, or, if sent by registered mail, on the fourth
day following the date presented to the postal authorities for delivery to the other party (the cancellation date stamped on the envelope being evidence of the date of such delivery), or if by telex or facsimile, on the telex or facsimile date.
Either party may give to the other written notice of change of address, in which event any communication shall thereafter be given to such party as above provided at such changed address. 

  
 21 

 13.2 Publication. If either party shall desire to publish or present, orally or in
writing, including, without limitation at symposia, national or regional professional meetings, or to publish in journals or other publications, any Confidential Information of the other party derived from or in anyway related to its activities
under this Agreement, including without limitation Confidential Information of the other party relating to the Licensed Patents or the Licensed Know-How, such party shall first provide the other party with copies of the proposed presentation or
publication materials at least sixty (60) days in advance of the presentation or publication date. Within thirty (30) days after its receipt of such information, the party receiving such materials shall advise the other party whether it
consents to the disclosure of the submitted information. If the party receiving the materials does not provide its written consent thereto, the party desiring to publish or present shall modify the proposed presentation or publication to eliminate
the other party’s Confidential Information or cancel its plans for publications. The parties agree that publication can be delayed for an appropriate period of time in the event that either party reasonably determines that it needs time to seek
patent or other intellectual property counsel and/or protection of its Confidential Information. 
 13.3 Assignment. This Agreement
shall be binding upon and inure to the benefit of the parties hereto and their successors and assigns. Notwithstanding the foregoing, neither party hereto shall have the right to assign any of its rights or obligations under this Agreement without
the prior written consent of the other party; provided, however, that either party may assign this Agreement to either (a) a party that succeeds to all or substantially all of the assigning party’s business or assets
involving the Licensed Technology, whether by sale, merger, acquisition, other consolidation of such party with or into another party, operation of law or otherwise, so long as such assignee or transferee agrees in writing to be bound by the terms
and conditions of this Agreement, or (b) an entity that is an Affiliate of the assigning party at the time of such assignment. Notwithstanding the foregoing, upon a termination of the Columbia Agreement, the rights and obligations of Corixa
under this Agreement shall be assigned to Columbia. Upon a permitted assignment of this Agreement by a party, all references herein to such party shall be deemed a reference to the assignee. 

13.4 Waivers. The failure of a party hereto to enforce any provision of this Agreement shall not be construed as a waiver of other
breaches of the same nature or other covenants or conditions of this Agreement. 
 13.5 No Agency, Etc. This Agreement is not
intended to create, nor should it be construed as creating, an agency, joint venture, partnership or employer-employee relationship between Introgen and Corixa. Each party shall act solely as an independent contractor and shall have no right to act
for or to sign the name of or bind the other party in any way or to make quotations or to write letters under the name of the other party or to represent that the party is in any way responsible for any acts or omissions of such party. 

13.6 Force Majeure. Introgen and Corixa shall not be liable for loss, damage, detention or delay resulting from any cause whatsoever
beyond its reasonable control or resulting from a force majeure, including, without limitation, earthquake, fire, flood, strike, lockout, civil or military authority, insurrection, war, embargo, container or transportation shortage or delay of
suppliers due to such causes, and delivery dates shall be extended to the extent of any delays 

  
 22 

 
resulting from the foregoing or similar causes. The party so affected shall give prompt notice to the other party of such cause, and shall take whatever reasonable steps are necessary to relieve
the effect of such cause as rapidly as reasonably possible. The party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled and for thirty
(30) days thereafter, whichever is longer; provided, however, that such affected party commences and continues to take reasonable and diligent actions to cure such cause. 

13.7 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Washington, without
regard to its principles of conflicts of laws. 
 13.8 Public Announcements. During the term of this Agreement, the parties agree to
consult with each other before issuing any press release or making any public statement with respect to this Agreement or any other transaction contemplated herein and, except as may be required by applicable law or any listing agreement with any
national securities exchange, shall not issue any such press release or make any such public statement prior to obtaining the written consent of the other party. 

13.9 Disputes and Alternative Dispute Resolution. If Corixa and Introgen are unable to resolve any dispute, controversy or claim
arising out of or in relation to this Agreement or the breach, termination or invalidity hereof (each, a “Dispute”), either party may, by written notice to the other, have such Dispute referred to the Chief Executive Officers of the
respective parties for attempted resolution. The Chief Executive Officers of the respective parties shall attempt in good faith within thirty (30) days after such notice is received to resolve such Dispute. Any Dispute that cannot be settled
amicably by agreement of the parties pursuant to the preceding sentence shall be finally settled by binding arbitration in accordance with the Licensing Rules of the American Arbitration Association (“AAA”) then in force by three
(3) arbitrators appointed in accordance with said rules, unless the parties agree that such arbitration shall be conducted by a single arbitrator. If arbitration is initiated by Corixa, the arbitration shall occur in Austin, Texas, and, if
arbitration is initiated by Introgen, the arbitration shall occur in Seattle, Washington. The decision and/or award rendered shall be written, final, non-appealable and binding on both parties. The judgment rendered by the arbitrator(s) shall
include costs of arbitration, reasonable attorneys’ fees and reasonable costs for any expert and other witnesses. Nothing in this Agreement shall be deemed as preventing either party from seeking injunctive relief (or any other provisional
remedy) from any court having jurisdiction over the parties and the subject matter of the dispute as necessary to preserve either party’s name, proprietary information, trade secrets, know-how or any other proprietary rights. Judgment upon the
award may be entered in any court having jurisdiction, or application may be made to such court for judicial acceptance of the award and/or an order of enforcement as the case may be. 

13.10 Severability. If any provision of this Agreement is finally held to be invalid, illegal or unenforceable by a court or agency of
competent jurisdiction, that provision shall be severed or shall be modified by the parties so as to be legally enforceable (and to the extent modified, it shall be modified so as to reflect, to the extent possible, the intent of the parties) and
the validity, legality and enforceability of the remaining provisions shall not be affected or impaired in any way. 

  
 23 

 13.11 Amendments. Except as otherwise expressly provided herein, neither this Agreement
nor any provision hereof may be amended or waived except by a written instrument signed by the party against whom enforcement of the amendment or waiver is sought. 

13.12 Headings. The headings of the paragraphs and subparagraphs of this Agreement have been added for the convenience of the parties
and shall not be deemed a part hereof. 
 13.13 Counterparts. This Agreement may be executed in any number of counterparts, all of
which together shall constitute a single Agreement. 
 13.14 Final Agreement. This Agreement is the agreement of the parties hereto
with respect to the subject matter hereof and supersedes all other such prior agreements and understandings, including without limitation the Prior Agreement. 

  
 24 

 IN WITNESS WHEREOF, each of the parties has caused this Exclusive License Agreement to be
executed by its duly authorized representative. 
  

									
	CORIXA CORPORATION	  		 	INTROGEN THERAPEUTICS, INC.
					
	By:	 	 /s/ Mark McDade
	  		 	By:	 	 /s/ Mahendra G. Shah

	Name:	 	Mark McDade	  		 	Name:	 	Mahendra G. Shah
	Title:	 	President and COO	  		 	Title:	 	Vice President
				
	CHINOOK CORPORATION	  		 		 	
					
	By:	 	 /s/ Mark McDade
	  		 		 	
	Name:	 	Mark McDade	  		 		 	
	Title:	 	President	  		 		 	

  
 25 

 Exhibit A 

Reagents to be Supplied to Introgen 

1. Bacterially-produced MDA-7 protein, in full length and truncated forms. 

2. Polyclonal antibodies, crude and affinity purified, in a quantity not to exceed the quantity that can be generated from five
(5) rabbits. 

  
 1 

 Exhibit B 

Terms and Conditions of Purchase and Supply of Reagents 

In accordance with the terms and conditions of the Exclusive License Agreement to which this Exhibit A is attached (the
“Agreement”), any Licensed Technology provided by Corixa to Introgen shall be subject to the terms and conditions set forth below. Unless otherwise defined herein, all capitalized terms used herein shall have the respective meanings
given them in the Agreement. 
 1. Any other terms provided by Introgen in connection with any purchase order, the receipt or acceptance of
the reagents hereunder, or otherwise, which are different than, or in addition to, the terms hereof are hereby objected to by Corixa. Shipment of the reagents hereunder shall not constitute acceptance by Corixa of any conflicting terms and
conditions proposed by Introgen. 
 2. All shipments of reagents hereunder shall be F.O.B. Corixa’s place of manufacture and Introgen
shall bear the risk of loss and cost of transportation of such reagents. 
 3. Unless otherwise expressly agreed by Corixa in writing,
Introgen shall use the reagents only in accordance with the terms and conditions of the Agreement. 
 4. THE REAGENTS ARE SUPPLIED HEREUNDER
“AS IS” AND CORIXA HEREBY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES WITH REGARD TO THE REAGENTS, EXPRESS OR IMPLIED, AND SPECIFICALLY DISCLAIMS ANY OTHER EXPRESS OF IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE AND ANY OTHER STATUTORY WARRANTIES OR ANY WARRANTY OF PATENTABILITY OR NONINFRINGEMENT. 

5. In the event of any conflict between these terms and conditions of this Exhibit A and the Agreement, the terms and conditions
of the Agreement shall govern. 

  
 1 

 Exhibit C 

Research Program 
 Corixa
shall use reasonable efforts to perform the following services during the first year of the Research Program: 
  

	 	1.	Develop a monoclonal or further polyclonal antibody against MDA-7 protein; 

  

	 	2.	Develop an ELISA assay to quantitatively determine MDA-7 protein content in various samples; 

  

	 	3.	Develop MDA-7 protein in bacteria as a positive control for ELISA and Westerns; and 

  

	 	4.	Develop a FACS-based assay to monitor MDA-7 protein expression. 

 Corixa shall use reasonable
efforts to perform the following services during the second year of the Research Program: 
  

	 	1.	Expand polyclonal antibody production, as required and with reasonable quantities to be mutually agreed by the parties in writing; and 

 

	 	2.	Develop a FACS-based assay to co-monitor MDA-7 expression and downstream target gene (to be determined) in target cells. 

The parties agree that monoclonal development may be necessary, and Corixa will undertake such work upon Introgen’s reasonable request,
but Introgen shall bear all costs and expenses associated with such development (in addition to the other payments set forth in the Agreement, including, but not limited to, pursuant to Section 4.3). 

  
 1 

 Exhibit 1.9 

LICENSED PATENTS 
  

											
	 COUNTRY
	  	 APPLICATION NO.
	  	 FILING DATE
	  	 PATENT NO.
	 	  	 ISSUE DATE

	 US
	  	08/143,576	  	10/27/93	  	 	5,643,761	  	  	07/01/97
	 US
	  	09/221,268	  	12/23/98	  				  	
	 AU
	  	80883/94	  	10/24/94	  	 	695,540	  	  	11/26/98
	 CA
	  	2,174,354	  	10/24/94	  				  	
	 EP
	  	94932000	  	10/24/94	  				  	
	 HK
	  	98115996	  	12/28/98	  				  	
	 JP
	  	512754	  	10/24/94	  				  	
	 KR
	  	702185/1996	  	10/24/94	  				  	
	 US
	  	08/696,573	  	08/16/96	  	 	5,710,137	  	  	01/20/98
	 US
	  	09/251,124	  	02/16/99	  				  	
	 AU
	  	42319/97	  	08/15/97	  				  	
	 BR
	  	Not yet available	  	08/15/97	  				  	
	 CA
	  	2,263,750	  	08/15/97	  				  	
	 CN
	  	97179714	  	08/15/97	  				  	
	 EP
	  	97940569	  	08/15/97	  				  	
	 JP
	  	Not yet available	  	08/15/97	  				  	
	 KR
	  	10-1999-7002342	  	08/15/97	  				  	
	 MX
	  	991852	  	08/15/97	  				  	
	 NZ
	  	334034	  	08/15/97	  				  	
	 US
	  	09/040,981	  	3/18/99	  				  	
	 PCT
	  	PCT/US99/05996	  	3/18/99	  				  	

  
 1 

 Exhibit 10.2 

Third Party Patents 
 WO
98/28425, Filed December 22, 1997 

  
 1EX-10.22

 Exhibit 10.22 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

ASSET PURCHASE AGREEMENT 

THIS ASSET PURCHASE AGREEMENT is made as of this 6th day of November, 2009, by and among INTROGEN THERAPEUTICS, INC., a Delaware
corporation (“Introgen Therapeutics”) and INTROGEN TECHNICAL SERVICES, INC., a Delaware corporation (“Introgen Services”), as debtors and debtors-in-possession (each a “Seller” and together
“Sellers”), and POPE INVESTMENTS II LLC, a Delaware limited liability company (“Buyer”). 

WITNESSETH 
 WHEREAS,
Sellers are currently debtors and debtors-in-possession in a case under the Bankruptcy Code titled, In re Introgen Therapeutics, Inc. and Introgen Technical Services, Inc., Case No. 08-12442, in the Bankruptcy Court (the
“Bankruptcy Case”); 
 WHEREAS, Sellers intend to convey to Buyer Sellers’ assets, contracts and rights necessary or
useful for developing, obtaining regulatory approvals in the United States and abroad for, manufacturing, commercializing and marketing the Assets (defined below). 

WHEREAS, Buyer desires to acquire the assets, contracts and rights necessary to further develop, obtain regulatory approvals in the United
States and abroad for, manufacture, commercialize and market the Assets (defined below); 
 WHEREAS, Sellers and Buyer desire to set forth
their agreement with respect to the transfer of certain assets to, and the assumption of specified liabilities by, Buyer in exchange for the consideration specified herein; 

NOW THEREFORE, in consideration of the mutual promises contained herein, and intending to be legally bound, Sellers and Buyer do hereby agree
as follows: 
 ARTICLE I 

TRANSFER OF ASSETS 
 1.1
Assets. 
 (a) Transferred Assets. Except as to any Excluded Assets, Sellers hereby agree to contribute, convey, grant,
assign and transfer, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Order Approving Debtors’ Motion to Sell Property Under Section 363(b) of the Bankruptcy Code, dated October 8, 2009, as the same
may be amended pursuant to Section 3.2 below (the “Sale Order”) to Buyer at the Closing, and Buyer hereby agrees to accept from Sellers at the Closing, the following assets, properties, rights and privileges owned, used
or held for use by Sellers as described below (the “Assets”): 
 (1) All of Sellers’ interest, right and title to the
patents and related intellectual property rights listed on Schedule 1.1(0(1) (the “Transferred Intellectual Property Rights”); 

 (2) The contracts listed on Schedule 1.1(a)(2) (the “Assumed
Contracts”); 
 (3) All vials of Advexin owned by Sellers as of the date of this Agreement and not previously sold including,
specifically, without limitation, those vials and other items of personal property listed on Schedule 1.1(a)(3) (the “Transferred Personal Property”); 

(4) All of Sellers’ equity interest in VirRx; Inc., a Delaware corporation, which is understood to be a 49% interest, and all of
Seller’s rights under any shareholder agreements, investment contracts or other agreements effecting or related to the equity interest in VirRx; Inc., but subject to any restrictions on transfer set forth in any such agreements, provided,
however, that Sellers will use commercially reasonable efforts to resolve any transfer restrictions and effect the transfer; and 
 (5)
All other assets, materials, properties, rights and privileges owned, controlled, used or held for use by Sellers in connection with the Transferred Intellectual Property Rights, the Assumed Contracts and the Transferred Personal Property, or
relating to the programs listed on Schedule 1.1(a)(5) attached hereto (“Programs”), other than the Excluded Assets, including but not limited to trademarks, regulatory filings and correspondence, clinical, preclinical
and other data, documentation, biological materials, tangible research materials, and rights arising under or relating to any and all protective covenant, noncompetition, nonsolicitation, confidentiality or similar agreements relative to the Assets
or Programs, and rights or claims arising thereunder. 
 To the extent that any of the Assets for whatever reason are not or cannot be
conveyed, assigned or transferred by Sellers to Buyer at Closing (other than Additional Contracts which are dealt with separately herein), Sellers hereby agree to take such actions requested by Buyer as may be reasonably necessary (including but not
limited to granting Buyer a sublicense with respect to such Assets and maintaining any license required to be maintained for such sublicense to survive) to give Buyer the benefits of such Assets for no additional consideration beyond the Purchase
Price. 
 (b) Excluded Assets. “Excluded Assets” shall include the following: 

(1) The consideration delivered to Sellers pursuant to this Agreement; 

(2) All assets previously transferred to Crucell Holland, B.V. (“Crucell”) under, and all future royalties, payments and
contingent proceeds due to Sellers pursuant to, the Patent Purchase Agreement between Introgen Therapeutics and Crucell Holland B.V., dated May 15, 2009; 

(3) All assets previously transferred to Vivante GMP Solutions, Inc. (“Vivante”) under, and all future royalties, payments
and contingent proceeds due to Sellers pursuant to, the Asset Purchase Agreement between Sellers and Western General Holdings / Vivante GMP Solutions, Inc., dated June 1, 2009 (the “Vivante Agreement”); 

(4) 350 vials of Advexin previously sold to Moffitt Cancer Center; 

(5) All of Sellers’ right title and interest in and to any and all intellectual property that relates solely to or is useful solely for
Introgen Therapeutics’s FUS1 program; provided, however, that Sellers acknowledge and agree that none of the items listed in Schedules 1.1(a)(1), 1.1(a)(2) or 1.1 (a)(3) will be considered FUS1 intellectual property for purposes of this
provision; 
 (6) All causes of action arising under 11 U.S.C. § 542, 543, 544, 545, 546, 547, 548, 549 and 555; 

  
 2 

 (7) All causes of action instituted by Sellers before the Closing Date (together with any
underlying employment agreement, personnel agreement or similar agreement to the extent related to any such causes of action filed prior to the Closing Date), and all other causes of action brought by the Liquidating Trustee of the Sellers,
including, but not limited to, patent infringement claims that arose prior to the Closing Date, but excluding such patent infringement claims relating to the Assets, that have not been brought by the Sellers or Liquidating Trustee of the Sellers
prior to the Closing Date; 
 (8) All stock and other equity interests or financial or ownership interests in Sellers’ subsidiaries
and any other entities except as such may be transferred to Buyer in accordance with the provisions contained in Section 3.2(f) hereof; and 

(9) One Seagate BlackArmor® NAS 440 4TB external hard drive, Product SKU: ST340005SHA10G-RK; provided, however, that any data
relating to the Assets and stored on such hard drive, to which the Buyer has access pursuant to Section 6.1, shall not be excluded hereunder; and 

(10) All cash, cash equivalents, trade accounts receivable, and other receivables of Sellers; provided that any receivables derived from the
Assets and arising after Closing shall belong to Buyer and will not be an Excluded Asset 
 (c) Contract Designation Rights. 

(1) A Seller is a party to that certain Restated P53 and K-Ras Agreement by and among Aventis Pharmaceuticals Products Inc., Aventis Pharma
S.A., and Introgen Therapeutics, Inc. dated June 30, 2001, as supplemented or amended (the “Aventis Agreement”). Each Seller may be a party to other agreements or contracts (in addition to the Assumed Contracts) that support or
are valuable to the development or marketability of the Assets, but such additional contracts are under review. From the date hereof until 5:00 p.m. central time on November 30, 2009 (the “Contract Designation Period”), Buyer
shall have the option to make designations as to the transfer, assumption and assignment of any contracts or agreements (other than the Assumed Contracts) that were entered into prior to the filing of the bankruptcy case and to which either Seller
is a party that, as of the date of this Agreement, have not been rejected, assumed or assigned by Sellers (together with the Aventis Agreement, the “Additional Contracts”) by delivering to Sellers a notice (a “Transfer
Notice”) of Buyer’s election to request Sellers to seek approval from the Bankruptcy Court to transfer, assume and assign one or more of such Additional Contracts to Buyer. Upon receipt of a Transfer Notice for an Additional Contract,
Sellers shall promptly file and serve an appropriate motion reasonably acceptable to Buyer and Sellers seeking the Bankruptcy Court’s approval of the transfer, assumption and assignment of such Additional Contract to Buyer. Contracts to which
any of Sellers’ wholly-owned subsidiaries are a party and which, if any Seller had been party to them would have been an Additional Contract, shall be addressed under the procedures outlined in Section 3.2(f). 

(2) By written notice (a “Withdrawal of Transfer Notice”) to Sellers at least two business days prior to the hearing on the
Sellers’ motion to transfer, assume and assign any Additional Contract that was the subject of a prior Transfer Notice, Buyer may withdraw its Transfer Notice with respect to one or more Additional Contracts and the Sellers shall withdraw its
motion with respect to such designated Additional Contracts only. 
 (3) Sellers represent that as of the date of execution of this
Agreement, they have not rejected the Aventis Agreement and covenant and agree not to take any action specifically intended to reject the Aventis Agreement or any Additional Contract prior to the Closing Date. Buyer acknowledges that any Additional
Contracts that are not on Schedule 1.1(a)(2) and that have not been added to the list of Assumed Contracts filed with the bankruptcy court will be deemed rejected upon the effective date of Sellers’

  
 3 

 
Plan of Reorganization and Sellers’ agree that prior to the earlier of (i) the Closing Date, (ii) the termination of this Agreement, or (iii) 150 days after the confirmation
of Sellers’ Plan of Reorganization, Sellers shall not have the plan of reorganization deemed effective, although Sellers will continue to vigorously pursue confirmation of their Plan of Reorganization, and nothing in this
Section 1.1 will prevent Sellers from doing so. 
 1.2 Purchase Price; Contingent Royalty Payments. In
addition to assuming the Assumed Liabilities, Buyer agrees to pay to Sellers, in the aggregate, the following consideration for the Assets: 

(a) At Closing, cash, wired funds, or other immediately available funds in the amount of One Million Dollars ($1,000,000.00), as adjusted
pursuant to Section 5.3 (the “Purchase Price”); 
 (b) Subject to Section 1.2(c) below, Buyer
agrees to pay to Sellers, as additional consideration for the Assets, upon such date a Net Sales objective identified in this section is achieved in full, the payment amount set forth for such objective (each such payment, if any, a
“Contingent Royalty Payment”). 
 (1) At such time as Net Sales first exceed $50 million dollars in the aggregate, a
Contingent Royalty Payment of Five Million Dollars ($5,000,000); 
 (2) At such time as Net Sales first exceed $100 million dollars in the
aggregate, a Contingent Royalty Payment of Five Million Dollars ($5,000,000); and 
 (3) At such time as Net Sales first exceed $500
million dollars in the aggregate, a final Contingent Royalty Payment of Twenty Million Dollars ($20,000,000). 
 (c) Sellers acknowledge and
agree that Buyer is an investor and not the entity that will further develop the Assets; that Buyer intends to transfer or contribute its rights and obligations under this Agreement to P53, Inc. (the “Buyer Transferee”) prior to the
Closing Date pursuant to the provisions of Section 10.3; and that upon such transfer to the Buyer Transferee, Buyer shall be released from its obligations under this Agreement and the Buyer Transferee will assume all obligations of Buyer
under this Agreement including, without limitation, the obligation to pay any Contingent Royalty Payments and effective immediately upon such transfer, all references herein to “Buyer” shall mean the “Buyer Transferee”. The
obligation of the Buyer to make Contingent Royalty Payments when due shall be irrevocable and shall survive the Closing. In no case will the Purchase Price and all Contingent Royalty Payments exceed $31,000,000 in the aggregate to the Sellers. Buyer
will act in good faith in calculating Net Sales and will not attempt to circumvent the definition of Net Sales in any manner including through transactions with Affiliates of Buyer. 

(d) Sellers acknowledge and agree that on and after the Closing Date Buyer will own the Assets free and clear of Liens, Claims, interests and
Encumbrances, each as defined in the Sale Order and is under no obligation to pursue any particular course of action with respect to the development, pursuit of regulatory approvals for, manufacture, commercialization and marketing of the Assets.
Sellers acknowledge and agree that on and after the Closing Date any business decisions made by Buyer with respect to any of the Assets shall be solely in Buyer’s discretion, that Buyer may sell, transfer, assign or license some or all of the
Assets to third parties under such terms and conditions as it shall determine in its sole and absolute discretion, 

  
 4 

 
subject to Section 10.3 below and to Buyer’s obligation not to attempt to circumvent the definition of Net Sales as provided above, and that neither the Buyer nor any subsequent
purchaser, assignee, transferee, licensee or similarly situated Person shall have any obligation whatsoever to Sellers or its successors or assigns hereunder to (i) protect any patents that are part of the Assets or (ii) attempt to
monetize the Assets. 
 1.3 “As Is” Condition. Except as set forth in Article VII, the Assets shall be
conveyed to and accepted by Buyer on the Closing Date in an “as is,” “where is” and “with all faults” condition, free of any warranties or representations whatsoever, whether oral or written, express or implied, patent
or latent and each Seller EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND EACH SELLER EXPRESSLY
DISCLAIMS LIABILITY FOR LOSS OF PROFIT OR FOR INDIRECT, CONSEQUENTIAL OR COMMERCIAL LOSSES AND ALL OTHER OBLIGATIONS AND LIABILITIES (EXCEPT AS EXPRESSLY RETAINED BY SUCH SELLER HEREUNDER). 

1.4 Further Assurances. Each Seller, for itself and its respective successors and assigns, hereby covenants and agrees that,
without further consideration, at any time and from time to time after the Closing Date, it shall execute and deliver to Buyer such further instruments of sale, conveyance, assignment and transfer, and take such other action, all upon the request of
Buyer, in order to (a) further document or evidence the contribution, conveyance, grant, assignment, transfer and delivery of all or any portion of the Assets to Buyer, (b) assure and confirm to any other person the ownership of the Assets
by Buyer and (c) permit Buyer to exercise any of the franchises, rights, licenses or privileges intended to be contributed, granted, conveyed, assigned, transferred and delivered by each Seller to Buyer pursuant to this Agreement. 

ARTICLE II 
 ASSUMPTION
OF CERTAIN LIABILITIES 
 2.1 Assumed Liabilities. 

(a) Assumed Liabilities. Buyer hereby agrees to assume at the Closing the following items (the “Assumed Liabilities”):

 (1) All obligations under Assumed Contracts arising on or after the Closing Date and $25,000 of the Cure Amount pursuant to the
Modification and Assignment Option Agreement among Introgen Therapeutics, Pope Investments II LLC and the Trustees of Columbia University in the City of New York, New York in the form attached hereto as Schedule 2.1(0(1); 

(2) Any costs or claims associated with any damages related to the removal and transport of the Assets by Buyer or the failure of Buyer to
comply with applicable law related to such removal and transport of the Assets. 
 (b) Excluded Liabilities. Except for those Assumed
Liabilities set forth in Section 2.1(a), at the Closing, Buyer shall not assume, and Sellers shall be solely and exclusively liable with respect to, all other liabilities and obligations of Sellers, including all Cure Amounts not
expressly assumed by Buyer in Section 2.1(a) (such liabilities and obligations being the “Excluded Liabilities”). 

2.2 Further Assurances. Upon the reasonable request of Sellers, at any time and from time to time after the Closing Date,
without further consideration, Buyer shall execute and deliver such further instruments of assumption and take such other actions as Sellers reasonably may require of Buyer to further document or evidence the assumption of the Assumed Liabilities,
including but not limited to the execution of 

  
 5 

 
such instruments as may be requested by any creditor, lessor or any other person whose consent is required to consummate the transactions contemplated by this Agreement. Upon the reasonable
request of Buyer, and upon the Bankruptcy Court’s approval of such request if such approval is required by law, at any time and from time to time after the Closing Date, without further consideration, Sellers agree to execute and deliver such
deeds, bills of sale, assignments or assurances and to take and do any other actions and things to vest, perfect or confirm of record or otherwise in Buyer any and all right, title and interest in, to and under any of the Assets acquired or to be
acquired by the Buyer as a result of, or in connection with, this Agreement. Pending the effective transfer thereof, Sellers agree to hold all rights or entitlements to such Assets in trust for the exclusive benefit of Buyer, provided that Buyer
shall pay, perform and discharge all obligations arising or accruing with respect thereto during the time that the Sellers shall hold such Assets in trust. Sellers agree that when a Liquidating Trustee is appointed, Sellers shall cause the
Liquidating Trustee to assume all obligations of the Sellers under this Agreement that survive the Closing. 
 ARTICLE III 

CONDITIONS TO OBLIGATIONS 

3.1 Conditions to Obligations of Sellers. All obligations of Sellers under this Agreement are subject to the fulfillment,
unless waived in writing at the sole option of Sellers, at or prior to the Closing Date, of each of the following conditions precedent: 

(a) Representations and Warranties. The representations and warranties of Buyer herein contained shall be true and correct as of the
date of this Agreement and shall be true and correct in all material respects (except that where any statement in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct) on and as of the
Closing Date, except that any representation or warranty which by its terms is made as of a specified date shall be true and correct in all material respects as of such specified date (except that where any statement in a representation or warranty
expressly includes a standard of materiality, such statement shall be true and correct) with the same force and effect as though made on and as of said date. 

(b) Covenants. Buyer shall have performed in all material respects all of the obligations and agreements and complied in all material
respects with all of the covenants contained in this Agreement to be performed and complied with by it at or prior to the Closing Date. 

(c) Closing Documents. Sellers shall have received all agreements, certificates, instruments and other documents required to be
delivered by Buyer on the Closing Date pursuant to Section 4.4, and the form and substance of all such agreements, certificates, instruments and other documents shall be reasonably satisfactory to Sellers. 

(d) Absence of Orders; Actions. No Law or Order shall have been enacted, entered, issued, promulgated or enforced by any Governmental
Entity which prohibits or materially restricts the transactions contemplated by this Agreement. 
 (e) Bankruptcy Court Orders. The
Sale Order shall be final and in full force and effect. 
 3.2 Conditions to the Obligations of Buyer: All obligations
of Buyer under this Agreement are subject to the fulfillment, unless waived in writing at the sole option of Buyer, at or prior to the Closing Date, of each of the following conditions precedent: 

(a) Representations and Warranties. The representations and warranties of Seller herein contained shall be true and correct as of the
date of this Agreement and shall be true and correct in all material 

  
 6 

 
respects (except that where any statement in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct) on and as of the Closing Date,
except that any representation or warranty which by its terms is made as of a specified date shall be true and correct in all material respects as of such specified date (except that where any statement in a representation or warranty expressly
includes a standard of materiality, such statement shall be true and correct) with the same force and effect as though made on and as of said date. 

(b) Covenants. Sellers shall have performed in all material respects all of the obligations and agreements and complied in all material
respects with all of the covenants contained in this Agreement to be performed and complied with by Sellers on or prior to the Closing Date. 

(c) Due Diligence Review. 

(1) Buyer shall have completed its due diligence review of the Assets, including verification of all schedules to this Agreement, and be
reasonably satisfied with the results thereof; and 
 (2) any matters discovered in Buyer’s due diligence review and brought to
Sellers’ attention must have been resolved to the reasonable satisfaction of Buyer. 
 (d) Crucell Amendment. Introgen
Therapeutics and Crucell shall have executed an amendment to the Assigned Patents License Agreement entered into as of May 15, 2009 between Introgen Therapeutics and Crucell (the “Crucell License”) in a form that is reasonably
satisfactory to Buyer and that clarifies (1) that the Crucell License covers all the Programs, (2) that if Buyer divides the Assets among different subsidiary or affiliated companies of Buyer after the Closing, that each of those
subsidiary or affiliated companies, and their respective successors, could be granted a sublicense by Buyer under the Crucell License for their particular Programs, and (3) that if Buyer or any of those subsidiary or affiliated companies, or
their respective successors, either (A) hires a third party contractor to manufacture any product resulting from a Program, (B) enters into an agreement with a third party to develop or commercialize any product resulting from a Program,
or (C) transfers to a third party substantially all its assets relating to a product resulting from a Program, they can grant that third party a sublicense under the Crucell License, with the right to grant sublicenses, with respect to such
product. 
 (e) Vivante Negotiations. To the extent that the Vivante Agreement purported to transfer to Vivante certain assets listed
in Schedule 3.2(e) attached hereto, Sellers shall have secured rights to such assets sufficient to transfer such assets to Buyer at Closing. 

(f) Matters Related to Subsidiaries. In the event that a wholly owned direct or indirect subsidiary of any Seller (each a
“Material Subsidiary”) owns, controls or holds assets, materials, properties, rights and/or privileges related directly to the Assets or otherwise necessary for Buyer to develop, obtain regulatory approvals for, manufacture,
commercialize and market the Assets (“Subsidiary Rights”), then either 
 (i) Buyer shall have received
evidence from Sellers satisfactory to Buyer, in its reasonable discretion, that all such Subsidiary Rights held by any such Material Subsidiary have either (1) been terminated, or (2) been completely transferred and assigned prior to
Closing or will be completely transferred and assigned to Buyer at the Closing, in each case without such Material Subsidiary retaining any rights associated therewith and in each case, free and clear of Liens, Claims, interests and Encumbrances,
each as defined in the Sale Order, except for Assumed Liabilities, or 
 (ii) Sellers shall transfer the equity interests in
any such Material Subsidiary to Buyer at Closing, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities. 

  
 7 

 (g) Additional Contracts. Sellers shall have made any filings with the Bankruptcy Court,
obtained any counter-party or other Approvals and taken all actions necessary or appropriate to transfer, assume and assign to Buyer all Additional Contracts designated on each Transfer Notice, if any, pursuant to Section 1.1(c), other
than any Additional Contracts set forth in a Withdrawal of Transfer Notice. 
 (h) Closing Documents. Buyer shall have received all
documents required to be delivered by Sellers on the Closing Date pursuant to Section 4.3. 
 (i) Absence of Orders;
Actions. No Law or Order shall have been enacted, entered, issued, promulgated or enforced by any Governmental Entity which prohibits or materially restricts the transactions contemplated by this Agreement. 

(j) Bankruptcy Court Orders. The Sale Order shall have been modified such that the benefits and protections that inure to Buyer under
the Sale Order will also inure to the benefit of Buyer’s permitted assigns and successors. In addition, the Sale Order or any amendment thereto shall be final and in full force and effect. Further, the Sale Order shall be modified as necessary
to provide for the reimbursement to Buyer by a third party buyer under the terms and conditions set forth in Section 5.4 hereof. 

(k) Approvals and Orders. Sellers shall have made any filings, taken all actions, and obtained any and all other Approvals and Orders
necessary or appropriate under the Bankruptcy Code and the Assumed Contracts for consummation of the sale of the Assets, the assumption by or assignment to the Buyer of the Purchased Contracts, subject to Sellers’ obligations to comply with any
order of the Bankruptcy Court, and shall have provided satisfactory evidence of same to Buyer. 
 ARTICLE IV 

CLOSING 
 4.1 Time
and Place. The Closing shall take place at the offices of Munsch, Hardt, Kopf & Harr, P.C. 600 Congress Ave., Suite 2900, Austin, Texas 78701, two (2) Business Days after the satisfaction or waiver of all conditions to Closing
set forth in Article III hereof (other than those conditions that by their nature cannot be satisfied until the time of Closing, but subject to the satisfaction or waiver of those conditions) or at such other time and place as Sellers and
Buyer may mutually agree (the “Closing Date”). 
 4.2 Closing Transactions. All documents and other
instruments required to be delivered at the Closing shall be regarded as having been delivered simultaneously, and no document or other instrument shall be regarded as having been delivered until all have been delivered. 

4.3 Deliveries by Sellers to Buyer. At the Closing, Sellers shall deliver or cause to be delivered to Buyer: 

(a) the certificate of incorporation (or comparable organizational documents) of each Seller certified by the Secretary of State of the State
of Delaware; 
 (b) a certificate executed by the CRO of each Seller, dated as of the Closing Date, to the effect that the conditions
specified in Section 3.2(a), (b), (e) and (k) are satisfied in all respects; 

  
 8 

 (c) such instruments of transfer and assignment for the Assets that Buyer may request to vest the
Assets in Buyer, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities, in accordance with terms of this Agreement; and 

(d) such other instruments and documents as are required by any other provisions of this Agreement or any agreement executed in connection
herewith to be delivered on the Closing Date by Sellers to Buyer. 
 4.4 Deliveries by Buyer to Sellers. At the Closing, Buyer
shall deliver or cause to be delivered to Sellers: 
 (a) the Purchase Price in accordance with the terms of this Agreement; 

(b) a certificate of the secretary or assistant secretary of Buyer certifying to: (i) the certificate of formation (or comparable
organizational documents) of Buyer; (ii) the resolutions of the board of directors (or other governing body) of Buyer approving the execution, delivery and performance of this Agreement, the Transaction Document to which Buyer is a party and
the consummation of the transactions contemplated hereby; and (iii) the incumbency and signatures of the officers of Buyer executing this Agreement and any other certificate or document delivered in connection herewith; 

(c) a certificate executed by the president, a vice president or the treasurer of Buyer, dated as of the Closing Date, to the effect that the
conditions specified in Section 3.1(a) and 3.1(b) are satisfied in all respects; 
 (d) the certificate of formation (or
comparable organizational documents) of Buyer certified by the Secretary of State of its jurisdiction of organization, a certificate of existence or good standing therefrom, as applicable, dated as of a recent date and a “bring-down”
telegram or certificate of good standing from such jurisdiction of organization dated as of a date within three (3) Business Days of the Closing Date; and 

(e) such other instruments and documents as are required by any other provisions of this Agreement or any agreement executed in connection
herewith to be delivered on the Closing Date by Buyer to Sellers. 
 ARTICLE V 

PAYMENT OF PURCHASE PRICE AND SALE/CLOSING 

5.1 Payment of Purchase Price. At the Closing and in consideration for the sale, transfer and assignment of the Assets, Buyer
shall pay to Sellers the Purchase Price. 
 5.2 Allocation of Purchase Price. The Purchase Price and Contingent Royalty
Payments shall be allocated among the Assets in a manner mutually agreeable to Buyer and Seller. Buyer shall prepare such allocation and deliver it to Seller for approval, which approval will not be unreasonably withheld. Buyer and Seller will
utilize the agreed upon allocation in all applicable tax filings. 
 5.3 Deposit. Immediately upon the execution and delivery
of this Agreement, Buyer shall tender to Sellers a deposit in the amount of One Hundred Thirty-Eight Thousand Dollars ($138,000.00) (the “Deposit”) as consideration for Buyer’s option to terminate this Agreement under
Section 8.1(a) and other purposes. The Deposit shall be made payable to Sellers in the form of a wire transfer (wire instructions to be provided upon request) or cashier’s check. At the Closing, the Deposit shall be credited against
the Purchase Price. 

  
 9 

 5.4 Reimbursement of Deposit. Other than as set forth below with respect to a
termination under Section 8.1(f), if this Agreement is terminated for any reason including because the bankruptcy court allows another third party to purchase the Assets, then if either or both of Sellers sell Assets or any part thereof
to one or more third-party purchasers within 365 days of the termination of this Agreement, then the Sellers shall obligate the third-party purchaser(s), as a condition of the sale, to reimburse Buyer for the Deposit and any Patent Funds, any
Storage Costs and any Additional Patent Costs and storage costs paid by Buyer pursuant to Section 6.6 and Section 8.1(c), and this obligation of Sellers shall continue in any subsequent sales or transfers of Assets until the
full amount has been reimbursed to Buyer. If this Agreement is terminated by Sellers pursuant to Section 8.1(f), then the Deposit, any Patent Funds, and Storage Costs and any Patent Costs and storage costs paid by Buyer shall not be
refundable or repaid to Buyer but shall be forfeited by Buyer. 
 ARTICLE VI 

COVENANTS 
 6.1
Access. 
 (a) Each Seller and Buyer agrees that it shall preserve and keep the books and records held by it, its subsidiaries
or its controlled Affiliates relating to the Assets for a period of three (3) years from the Closing Date. Each Seller agrees to take, and to cause any of its subsidiaries or Affiliates to take, such steps as are reasonably necessary to protect
the confidentiality of such books and records during such time period and shall not disclose to any third party any portion thereof which would reasonably be expected to be confidential with respect to the Assets, including without limitation,
procedures relative to Programs, research, studies, test results related to the Programs and Transferred Intellectual Property, without the prior written consent of Buyer. 

(b) Sellers shall give Buyer reasonable access, during normal business hours and upon reasonable prior written notice, including making
available at reasonable times and to a reasonable extent Sellers’ officers and employees to discuss Sellers’ business associated with the Assets with Buyer’s representatives (including representatives of Buyer’s proposed
financiers or lenders) and their counsel, to review and/or photocopy (A) all books, records, accounts and documents of Sellers relating to the assets, properties and operations of its business associated with the Assets including, without
limitation, all computer data files stored, used, held or kept in connection with the operation of its business, and (B) all mailing lists and customer lists used by Sellers in or relating to its business associated with the Assets. Buyer shall
have the right at its own expense to make copies of such materials to the extent that they relate to the operations of Sellers’ business associated with the Assets. Seller agrees to use its reasonable efforts to take or cause to be taken all
action and to assist and cooperate with Buyer in good faith to consummate and make effective the transactions contemplated hereby, including: (a) using Sellers’ reasonable best efforts to provide in a timely manner all materials and
information requested by Buyer to complete its due diligence review and to take all actions reasonably necessary to satisfy the closing conditions, (b) the obtaining of applicable consents, waivers or approvals of any third parties required
under the terms of the Assumed Contracts, (c) the defending of any proceeding challenging this Agreement or the performance of the obligations hereunder, and (d) the execution and delivery of such instruments and the taking of such other
actions as Buyer may reasonably request in order to consummate the terms of this Agreement. 
 (c) For a period of three (3) years from
the Closing Date, Buyer shall give Sellers reasonable access, during Buyer’s normal business hours and upon reasonable prior written notice, to all 

  
 10 

 
books and records of Buyer relating to the operation of Sellers’ business associated with the Assets prior to the Closing Date or to any Excluded Liabilities including, without limitation,
all relevant computer data files stored, used, held or kept in connection with the operation of Sellers’ business, to the extent such files are in Buyer’s possession; provided that as a condition to such access Sellers shall have executed
and delivered a confidentiality agreement reasonably satisfactory to Buyer; provided further that the purpose and extent of such access shall be as necessary in connection with either (i) the contest or defense of any Action brought against
Sellers involving facts, events or circumstances relating to its business associated with the Assets or the Excluded Liabilities, or (ii) the preparation of any Tax return, election, contest or claim for Tax refund or any audit, examination or
proceeding with respect to the Taxes of Sellers. Sellers shall have the right at their own expense to make copies of such materials to the extent that they relate to the operations of Sellers’ business associated with the Assets prior to the
Closing Date or to any Excluded Liabilities. 
 6.2 Insurance. Effective at 12:01 a.m. on the date following the Closing Date,
all insurance coverage maintained by Sellers under which the Assets are insured, including any and all bonds and indemnity obligations, shall be canceled and terminated (except to the extent that they may not, by their terms, be so canceled or
terminated). All premium refunds paid to Sellers relating to such insurance covering the Assets shall be the property of Sellers regardless of whether such refunds are paid on, before or after the Closing Date. 

6.3 Public Announcements. Neither Buyer nor Sellers shall issue any press releases or otherwise make any public statements with
respect to this Agreement or the transactions contemplated hereby without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed. At or after the Closing, it is hereby acknowledged and agreed that Buyer
and Sellers may issue press releases or make public statements regarding this Agreement and the transactions contemplated hereby without the prior consent of the other. 

6.4 Updating of Schedules. The parties acknowledge that the schedules attached to this Agreement were prepared in haste and may
need to be updated prior to Closing based on due diligence results. Sellers or Buyer may, at least three (3) days prior to the Closing, deliver updated schedules, if applicable, to reflect changes to the schedules, which schedules must be
reasonably acceptable to the other party, such acceptance not to be unreasonably withheld, prior to Closing. 
 6.5 Purchased
Contracts. 
 (a) Subject to the approval of the Bankruptcy Court and pursuant to the Sale Order, the Purchased Contracts will be
assumed by Sellers and sold and assigned to Buyer (or Buyer’s designee) at the Closing free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities, on the Closing Date under
Sections 363(f), 365(a) and 365(b) of the Bankruptcy Code. 
 (b) If after the date hereof (including after the Closing Date), Buyer or
Sellers discover a contract which Buyer in good faith believes should have been treated as an Assumed Contract hereunder and for which Buyer had not been given reasonable opportunity prior to Closing to review and include such contract as an
Assumed Contract and if such contract has not been otherwise assigned to a third party after the Closing, Buyer and Sellers shall take such action and execute such agreements as may be appropriate to effect Buyer’s assumption and Sellers’
assignment of such contract, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities. 

  
 11 

 6.6 Pre-Closing Covenants. 

(a) Payment of Costs by Buyer. 

(1) Buyer hereby agrees that during the period from the execution of this Agreement by Buyer and Sellers until the earlier of Closing,
November 30, 2009 (unless such date is extended as provided herein), or the termination of this Agreement, Buyer will be responsible for paying all out of pocket costs and expenses of maintaining only the patents listed on
Schedule 6.6(a) attached hereto and incorporated herein by reference which shall be capped at $87,000 in the aggregate (the “Patent Costs”). Buyer will also be responsible for paying the costs of storing the files and
data currently being stored by Sellers at the Greenspoint location for periods beyond October 31, 2009 (or of moving such items and storing them elsewhere for such periods), and the cost of storing the vials included in the Transferred Personal
Property currently being stored with Vivante GMP Solutions, Inc. beyond November 30, 2009 (collectively, the “Storage Costs”). All Storage Costs (and all agreements related thereto including any leases or rental agreements) to
be paid under this Section 6.6(a)(1) or under Section 8.1(c) shall be subject to approval by Buyer, such approval not to be unreasonably withheld or delayed. 

(2) Upon execution of this Agreement by Buyer and Sellers, Buyer will deliver $87,000 in cash or wired funds (the “Patent
Funds”) to Munsch Hardt Kopf & Harr, P.C., counsel to Sellers (“MHKH”), to be held by MHKH and utilized to cover the Patent Costs, some of which were paid prior to the execution of this Agreement by the Sellers, in
which case the Patent Funds will be used to reimburse Sellers for Patent Costs listed on Schedule 6.6(a) and paid by Sellers prior to execution of this Agreement. MHKH will apply the Patent Funds to the Patent Costs as needed to maintain
the patent related Assets. Sellers will provide Buyer with (i) an itemized list of all Patent Costs paid out of the Patent Funds and (ii) proof reasonably satisfactory to the Buyer that the Patent Costs have been paid according to
Schedule 6.6(a). Any Patent Funds not utilized to pay Patent Costs will be refunded to Buyer at Closing or applied to the Purchase Price. 

(3) Buyer and Sellers acknowledge that Storage Costs for Greenspoint have been paid through October 31, 2009, and Storage Costs for
Vivante have been paid through November 30, 2009, and Buyer is not responsible for such Storage costs already paid. Buyer and Sellers further acknowledge and agree that the amount of the Storage Costs for the items at Greenspoint beyond
October 31, 2009, are not currently known, but once they have been determined buyer will promptly pay them subject to the provisions of Section 6.6(a)(1) above. 

(4) Sellers agree that Buyer may, pending Closing and subject to prior notice to Sellers, take such actions as Buyer desires to maintain any
trademarks that are part of the Assets. Buyer acknowledges that Sellers have not generally been taking actions to maintain trademarks and that therefore some trademarks may have lapsed or expired. Buyer agrees to notify Sellers in advance of all
actions taken by Buyer to maintain trademarks prior to Closing. 
 (b) Notification of Certain Matters. Buyer and Sellers
shall promptly notify the other parties to this Agreement of (a) the occurrence or non-occurrence of any fact or event which would be reasonably likely (i) to cause any representation or warranty contained in this Agreement to be untrue or
inaccurate in any material respect at any time from the date hereof to the Closing Date, or (ii) to cause any material covenant, condition or agreement hereunder not to be complied with or satisfied in all material respects, and (b) any
failure of Buyer or Sellers to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder in any material respect. 

(c) Conduct of Business. Except as otherwise contemplated by this Agreement and as Buyer may otherwise consent in writing, until
the Closing: 
 (1) Sellers will not amend, change, terminate or otherwise modify any Purchased Contracts; 

  
 12 

 (2) Sellers will not sell, transfer, mortgage, encumber or otherwise dispose of any of the
Assets; and 
 (3) Sellers will use reasonable efforts to preserve the Assets. 

(d) Approvals and Best Efforts. Each Seller and Buyer will use its commercially reasonable best efforts to obtain as promptly as
practicable all Approvals of any Governmental Entity or other Person required in connection with the consummation of the transactions contemplated by this Agreement. In addition, subject to the terms and conditions herein provided, each Seller and
Buyer covenants and agrees to use its commercially reasonable best efforts to take, or cause to be taken, all action or do, or cause to be done, all things necessary, proper or appropriate to consummate and make effective the transactions
contemplated hereby, to satisfy the conditions in Sections 3.1 and 3.2 and to cause the fulfillment of the parties’ obligations hereunder. 

(e) Bankruptcy Court Approval. 

(1) Each Seller and Buyer acknowledge that Sellers have obtained the Sale Order from the Bankruptcy Court authorizing the sale of the Assets
to Buyer under the terms set forth herein. 
 (2) Sellers shall promptly make any filings, take all actions, and use commercially
reasonable best efforts to obtain any and all other Approvals and Orders necessary or appropriate for consummation of the sale of the Assets or the assumption of the Purchased Contracts, subject to its obligations to comply with any order of the
Bankruptcy Court. 
 (3) In the event an appeal is taken, or a stay pending appeal is requested, from the Sale Order, Sellers shall
immediately notify Buyer of such appeal or stay request and shall promptly provide to Buyer a copy of the related notice of appeal or order of stay. 

(f) Transfer Taxes. In accordance with Section 1146(c) of the Bankruptcy Code, the making or delivery of any instrument of
transfer, including the filing of any deed or other document of transfer to evidence, effectuate or perfect the rights, transfers and interest contemplated by this Agreement, shall be in contemplation of a plan or plans of reorganization to be
confirmed in the Bankruptcy Case, and as such shall be free and clear of any and all transfer Tax, stamp Tax or similar Taxes. Such instruments transferring the Assets to Buyer shall contain the following endorsement: 

“Because this [instrument] has been authorized pursuant to Order of the United States Bankruptcy Court for the Western District of Texas,
Austin Division, in contemplation of a plan of reorganization of the Grantor, it is exempt from transfer taxes, stamp taxes or similar taxes pursuant to 11 U.S.C, 1146(c).” 

6.7 Bankruptcy Filings. From and after the date hereof until the Closing Date, Sellers shall provide Buyer the opportunity to
review and comment reasonably on all documents, motions, orders, filings or pleadings that Sellers file in the Bankruptcy Court which relate to the consummation or approval of the sale of the Assets and this Agreement and will consider all
reasonable comments of Buyer. Further, without the prior written consent of Buyer, the Sellers shall not seek to amend or modify any provision of the Sale Order to effect a change in terms and conditions of the transactions contemplated by this
Agreement which would 

  
 13 

 
reasonably be expected to have a material adverse effect on the Buyer or on the ability of the Sellers and the Buyer to consummate the transaction contemplated hereby. Sellers will also promptly
provide Buyer with facsimile or electronic copies of all pleadings received by or served by or upon the Sellers in connection with the Bankruptcy Case, which, to Sellers’ knowledge, have not otherwise been served on Buyer. 

6.8 Turnover of Payments. In the event that Buyer receives any payment or instrument of payment of any amount included in the
Excluded Assets or any other payment or amount to which Sellers are entitled, Buyer shall deliver the same promptly to Sellers (with endorsement, if necessary, but otherwise in the same form as received) and, until so delivered, hold the same in
trust for Sellers’ benefit and as property of Sellers. In the event that Sellers receive any payment or instrument of payment of any amount included in the Assets or any other payment or amount to which Buyers are entitled, Sellers shall
deliver the same promptly to Buyer (with endorsement, if necessary, but otherwise in the same form as received) and, until so delivered, hold the same in trust for Buyer’s benefit and as property of Buyer. 

6.9 Post-Closing Covenants and Reports. Buyer agrees to remove all Assets from the location where Sellers are keeping them on or
before ten (10) days following Closing. Buyer will arrange for and pay for all shipping and delivery of the Assets, will bear the risk of loss of the Assets as soon as they leave the location Sellers are storing them, and shall be responsible
for insuring the Assets during and after they leave Sellers’ possession. Buyer agrees that it will provide quarterly reports to Sellers detailing all Net Sales for the immediately preceding quarter, and also providing a calculation of the
aggregate Net Sales since the Closing Date (each a “Net Sales Report”). 
 6.10 HIPPA Compliance. Buyer
agrees that it will comply in all respects with all requirements of the Health Insurance Portability and Accountability Act of 1996, Public Law 104-191 (“HIPAA”) in connection with Buyer’s purchase and use of the Assets. It is
specifically agreed that Buyer shall only be responsible for privacy and other HIPPA requirements arising from Buyer’s activities and Buyer shall not be responsible hereunder for privacy or any other HIPPA requirements of any third party
arising before or after the Closing Date. Buyer agrees not to disclose or use any protected health information or other confidential information that is part of the Assets or is received by or disclosed to Buyer in connection with the sale of the
Assets to Buyer, except in compliance with HIPAA and any rules, regulations and laws promulgated under or in connection with HIPAA. Buyer agrees to defend, indemnify and hold Sellers and each Seller’s shareholders, officers, directors,
employees, attorneys, agents, successors and assigns (a “Seller Indemnified Party”), harmless from and against any and all costs, expenses, damages, claims, causes of action, and liabilities arising from or related to any failure of
Buyer to comply with its obligations hereunder. Sellers, for themselves and each other Seller Indemnified Party, acknowledge and agree that Sellers’ sole remedy for the breach of this Section 6.10 shall be limited to seeking
enforcement of the indemnification obligations set forth in the immediately preceding sentence. Any Seller Indemnified Party claiming indemnification under this Section must promptly (i) notify Buyer of any claim asserted against the Seller
Indemnified Party which could give rise to a right of indemnification under this Section 6.10 and (ii) transmit to Buyer a written notice (a “Claim Notice”) describing in reasonable detail the nature of the claim, a
copy of all papers served with respect to that claim (if any), an estimate of the amount of damages attributable to that claim to the extent feasible (which estimate will not be conclusive of the final amount of that claim) and the basis for the
Seller Indemnified Party’s request for indemnification under this Agreement. Failure to promptly deliver a Claim Notice will not relieve Buyer of its obligations to the Seller Indemnified Party with respect to the related claim except to the
extent that the resulting delay is materially prejudicial to the defense of that claim. Within 15 days after receipt of any Claim Notice, Buyer must notify the Seller Indemnified Party providing a Claim Notice whether (i) Buyer disputes its
potential liability to the Seller Indemnified Party under this Section 6.10 with respect to that claim and (ii) whether Buyer desires at the sole cost and expense of Buyer, to control the defense of such claim, or if Buyer desires
to allow Sellers to control the defense of such claim at Buyer’s sole cost and expense. If Buyer elects to control the defense of such claim, then the Seller Indemnified Party may participate in, but not control, any defense or settlement of
any claim controlled by the Buyer pursuant to this Section 6.10 and shall bear its own costs and expenses with respect to such participation. 

  
 14 

 6.11 Audit Rights. Sellers have the right at any time and from time to time, but
not more than twice in a given 12 month period, on at least five (5) days advance notice, to audit and analyze Buyer’s records related to the Assets to verify compliance with this Agreement and the accuracy of any Net Sales Reports. An
independent auditor selected by Sellers will conduct each such audit. The Sellers will pay the auditor’s fees and expenses, unless the audit establishes that there were inaccuracies in the Buyer’s Net Sales Reports that result in an
under-calculation of [***] of Net Sales, in which case Buyer will promptly pay the auditor’s reasonable fees and expenses. If the audit determines that amounts are due hereunder, Buyer will promptly pay such amounts. Buyer may hire a separate
independent auditor to confirm the results of any such audit before paying any amounts alleged to be due pursuant to the audit. In the event that Buyer sells, transfers, assigns or licenses all or part of the Assets to a third party which is not an
Affiliate of Buyer, as a condition of such action Buyer shall require that such third party provide Net Sales information to Sellers until such time as aggregate Net Sales equal $500,000,000, with Seller audit rights similar in all material respects
to those set forth in this Section 6.11. Notwithstanding the foregoing, Buyer shall have no obligation hereunder with respect to (i) the accuracy of any Net Sales information provided by any such third party, or (ii) to pursue
legal or other action against such third party for the enforcement of such audit and reporting provisions unless all costs thereof shall be paid by Sellers. 

ARTICLE VII 

REPRESENTATIONS AND WARRANTIES 

7.1 Sellers. Each Seller, severally and not jointly, represents and warrants the following: 

(a) It is a corporation duly organized and validly existing under the laws of the State of Delaware with all necessary corporate power and
authority to execute, deliver and perform this Agreement 
 (b) The execution, delivery and performance of this Agreement by it and the
other agreements being executed and delivered in connection with this Agreement (the “Transaction Documents”) by it to Buyer have been duly and validly authorized by all necessary corporate action on its part, and this Agreement and
the other Transaction Documents constitute its valid and legally binding obligation, enforceable against it in accordance with their respective terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application now or hereafter in effect affecting enforcement of creditors’ rights generally and (ii) general principles of equity. 

(c) At the Closing, it possesses, and is hereby transferring good and indefeasible title to the Assets to Buyer free and clear of Liens,
Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities, and with all of the protections afforded by, Section 363 of the Bankruptcy Code and Sellers have not sold, transferred, assigned or licensed,
in whole or in part, any of the Transferred Intellectual Property Rights. 
 (d) The execution and delivery of this Agreement and the other
Transaction Documents to which such Seller is a party and the consummation of the transactions contemplated hereby will not result in any violation, or be in conflict with or constitute, with or without notice or the passage of time, a default under
any provision of such Seller’s certificate of incorporation or bylaws, or any Order or contract to which such Seller is a party or by which it or any of its assets and properties are bound. 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 15 

 (e) Seller has provided true and complete copies of (i) all the Assumed Contracts,
(ii) the asset purchase agreement between Vivante GMP Solutions, Inc. and Sellers, (iii) the patent purchase and license agreements between Crucell Holland B.V. and Introgen Therapeutics and (iv) the Restated p53 and K-ras Agreement
between Aventis Pharmaceuticals Products Inc., Aventis Pharma S.A. and Introgen Therapeutics and to the knowledge of Sellers, there are no other contracts or agreements, written or oral, enforceable or unenforceable, related to any of the agreements
set forth in (i) - (iv) of this Section 7.1(e). 
 (f) To the knowledge of Seller, as used in Seller’s business, none
of the Transferred Intellectual Property Rights infringes upon, misappropriates, or violates any proprietary rights of third parties. To the knowledge of Sellers, no Person has asserted or threatened to assert any claim with respect to the
Transferred Intellectual Property Rights (1) to the effect that the Transferred Intellectual Property Rights, as used in Sellers’ business, infringe or misappropriate, or have infringed or misappropriated, any copyright, patent, trademark,
trade secret or other intellectual property right of any other Person or (2) challenging the ownership, validity, enforceability or effectiveness of any of the Transferred Intellectual Property Rights. To the knowledge of Seller, no Person is
or is suspected of infringing upon, misappropriating of have misappropriated or infringed upon, any copyright, patent, trademark, trade secret or other intellectual property right of any of the Assets. 

7.2 Buyer. Buyer represents and warrants the following: 

(a) Buyer is a limited liability company duly organized and validly existing and in good standing under the laws of the State of Delaware with
all necessary power and authority to execute, deliver and perform this Agreement. 
 (b) The execution, delivery and performance of this
Agreement and the other Transaction Documents by Buyer have been duly and validly authorized by all necessary action on the part of Buyer, and this Agreement and the other Transaction Documents constitute the valid and legally binding obligation of
Buyer, enforceable against Buyer in accordance with their respective terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application now or
hereafter in effect affecting enforcement of creditors’ rights generally and (ii) general principles of equity. 
 (c) The
execution, delivery and performance of this Agreement, the other Transaction Documents to which Buyer is a party and the consummation of the transactions contemplated hereby will not result in any violation or be in conflict with or constitute, with
or without notice or the passage of time and giving of notice, a default under any provision of Buyer’s constituent documents or any Order or contract to which Buyer is a party or its respective assets or properties are bound. 

(d) As of the date of this Agreement, Buyer is not aware of, and has no knowledge of, any other contract, agreement, or document that Buyer
believes should be an Additional Contract, or with respect to which Buyer intends to send a Transfer Notice. 
 ARTICLE VIII 

TERMINATION 
 8.1
Termination. This Agreement may be terminated prior to the Closing and the transactions contemplated hereby may be abandoned in accordance with the following: 

(a) This Agreement may be terminated by Buyer, by written notice to Sellers based on the results of the Buyer’s due diligence on the
Assets pursuant to Section 3.2(c) not being reasonably satisfactory to Buyer, provided that any such notice shall specify the particular due diligence issues resulting in the termination. 

  
 16 

 (b) This Agreement may be terminated at any time by the mutual written consent of Buyer and
Sellers. 
 (c) This Agreement may be terminated by Sellers upon written notice from Sellers to Buyer if the Closing has not taken place on
or prior to November 30, 2009; provided, however, that Sellers may only terminate this Agreement pursuant to this Section 8.1(c) if the failure to close is not the result of a breach by Sellers of any material provision contained in
this Agreement, including but not limited to Section 6.1(b); and further provided, that Buyer will have the option to extend the date in this Section 8.1(c) to December 31, 2009 by providing written notice to Sellers of
Buyer’s desire to extend and Buyer’s agreement to pay the out of pocket costs and expenses necessary to maintain the patents that Buyer desires to acquire. No later than November 27, 2009, Buyer shall deliver to Sellers the
December docket marked to show which patents Buyer desires to maintain and Buyer and Sellers shall work together to agree on the amount of maintenance fees and reasonable legal fees to be paid to Wall (the “Additional Patent
Costs”) and (ii) the Storage Costs through December 31, 2009. In the event Buyer exercises its right to extend under this Section 8.1(c), Buyer shall promptly deliver an amount equal to the Additional Patent Costs (the
“Additional Patent Funds”) in cash or wired funds to MHKH to be held by MHKH and utilized to cover the Additional Patent Costs, and shall pay the Storage Costs through December 31, 2009, MHKH shall apply the Additional Patent
Funds to the Additional Patent Costs as needed to maintain the patent related Assets. Sellers will provide Buyer with (i) an itemized list of all Additional Patent Costs paid out of the Additional Patent Funds and (ii) proof reasonably
satisfactory to the Buyer that the Additional Patent Costs have been paid. Any Additional Patent Funds not utilized to pay Additional Patent Costs will be refunded to Buyer at Closing or applied to the Purchase Price. 

(d) This Agreement may be terminated by Sellers upon written notice from Sellers to Buyer if the Closing has not taken place on or prior to
November 30, 2009; provided, however, that Sellers may only terminate this Agreement pursuant to this Section 8.1(d) if the failure to close is not the result of a breach by Sellers of any material provision contained in this
Agreement, including but not limited to Section 6.1(b), and if all conditions under Section 3.2 (other than Section 3.2(c)(1)) have been satisfied; provided further that if Buyer has notified Sellers of anything
that Buyer has discovered in its due diligence review that has not yet been corrected or resolved to Buyer’s reasonable satisfaction, including specifically, without limitation, any Additional Contracts which have been designated in a Transfer
Notice in accordance with Section 1.1(c) hereof and not yet transferred to Buyer or a Cure Amount has not been agreed upon with a third party or established by the Bankruptcy Court, or an agreement has not been reached between Buyer and
Sellers as to who should pay the Cure Amount or in what proportions, Sellers may not terminate under this provision until such time as the matter has been resolved to Buyer’s reasonable satisfaction. 

(e) This Agreement may be terminated by Buyer or Sellers, upon written notice to the other, if there shall be in effect a non-appealable order
of a court of competent jurisdiction permanently prohibiting the consummation of the transactions contemplated hereby. 
 (f) This Agreement
may be terminated by Sellers if Buyer is in material breach of any material covenant or agreement under this Agreement, or if any representation or warranty of Buyer is not true and correct in all material respects (except that where any statement
in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct), in either case such that the conditions set forth in Sections 3.1(a) and (b) would not be satisfied and
which is not curable or, if curable, is not cured within thirty (30) calendar days after written notice of such breach is given to Buyer by Sellers. 

(g) This Agreement may be terminated by Buyer if Sellers are in material breach of any material covenant or agreement under this Agreement, or
if any representation or warranty of Sellers is not true and correct in all material respects (except that where any statement in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct),
in either case such that the conditions set forth in Sections 3.2(a) and (b) would not be satisfied and which is not curable or, if curable, is not cured within thirty (30) calendar days after written notice of such
breach is given to Sellers by Buyer. 

  
 17 

 8.2 Status of Agreement after Termination. Upon any termination of this Agreement
pursuant to Section 8.1, this Agreement shall become void and shall have no effect, except for those obligations in Sections 5.3, 5.4, 6.3, 6.8 and 10.4, each which shall survive the termination of
this Agreement in accordance with its terms. 
 8.3 Survival. The representations, warranties, agreements or covenants of the
parties made in this Agreement, and any rights arising out of any breach of any such representation, warranty, agreement or covenant, shall not survive beyond the Closing Date, except for those covenants or agreements of the parties which by their
terms contemplate performance after the Closing Date and the following provisions, all of which shall survive the Closing Date subject to the terms hereof: Sections 1.1(a), 1.1(c), 1.2(b), 1.2(c), 1.4, 2.2, 5.2, 6.1(b), 6.1(c), 6.5(b),
6.6(a) ,6.8, 6.9, 6.10, 6.11, 8.3 and Article X. 
 ARTICLE IX 

CERTAIN DEFINITIONS 
 As
used in this Agreement, the following definitions shall apply: 
 9.1 “Action” means any charge, claim, lawsuit,
complaint, request for investigation, report of alleged violation of law or regulation, or legal proceeding of any nature filed with or made to any Governmental Entity or organization having jurisdiction or authority over Sellers, their assets,
their property or their operations. 
 9.2 “Affiliate” means a Person that directly, or indirectly through one or
more intermediaries, controls, or is controlled by, or is under common control with, a specified Person. 
 9.3
“Agreement” means this Asset Purchase Agreement by and between Buyer and Sellers, as amended or supplemented, together with all schedules attached hereto. 

9.4 “Approval” means any approval, authorization, consent, qualification or registration, or any waiver of any of the
foregoing, required to be obtained from, or any notice, statement or other communication required to be filed with or delivered to, any Governmental Entity or any other Person. 

9.5 “Bankruptcy Code” means 11 U.S.C, 101 et seq., and applicable federal rules of bankruptcy procedure thereunder.

 9.6 “Bankruptcy Court” means the United States Bankruptcy Court for the Western District of Texas, Austin
Division. 
 9.7 “Business Day” means a day that is not a Saturday, Sunday or legal holiday in Austin, Texas. 

  
 18 

 9.8 “Closing” means the closing of the transactions contemplated by this
Agreement. 
 9.9 “Cure Amount” shall have the meaning assigned to such term in the Sale Order. 

9.10 “Expenses” means reasonable attorneys’ and accountants’ fees and expenses, costs of investigation and
all other reasonable out-of-pocket expenses. 
 9.11 “Governmental Entity” means any government or any agency,
bureau, board, commission, court, department, official, political subdivision, tribunal or other instrumentality of any government, whether federal, state or local, domestic or foreign. 

9.12 “Laws” means any law, statute, regulation, rule, ordinance or Order of a Governmental Entity. 

9.13 “Lien” means any mortgage, pledge, deed of trust, hypothecation, lien, security interest, encumbrance, or other
similar restriction, claim or right of others. 
 9.14 “Net Sales” means the revenues actually received by Buyer,
any affiliate of Buyer, any subsequent transferees of any of the Assets, and any sublicensee of any of the foregoing, from all sales of Products anywhere in the world, less deductions for any: (a) credits, allowances, samples, discounts and
rebates actually granted to such customers (including those granted to managed-care entities and government agencies as well as entities that manage patient drug benefits); (b) freight and insurance costs actually paid only if stated on an
invoice; (c) trade, quantity or cash discounts; (d) retroactive price reductions actually given; and (e) sales, value-added and other direct taxes (including customs, duties and other similar governmental charges) incurred directly in
connection with the sales of Products to third party customers and actually paid only if stated on an invoice. In the event that a Product is sold for a single price in combination with another therapeutically active ingredient, or other product or
service which does not constitute a Product under this Agreement if sold separately, Net Sales from such combination sales for purposes of calculating Net Sales under Section 1.2 shall be calculated by multiplying the Net Sales of the
combination product by the fraction A/(A+B), where A is the average gross selling price during the previous calendar quarter of such Product sold separately and B is the average gross selling price during the previous calendar quarter of the
therapeutically active ingredient, or other product or service sold separately. In the event that separate sales of such Product or such additionally therapeutically active ingredient, or other product or service were not made during the previous
calendar quarter, then the Net Sales shall be reasonably allocated between such Product and such active ingredient, or other product or service, based upon their relative values, and if requested by any Seller on behalf of Sellers, Buyer (or its
permitted successors and assigns) and such Seller shall negotiate in good faith and agree on the proper allocation and relative values, such agreement not to be unreasonably withheld by either party. 

9.15 “Order” means any decree, injunction, judgment, order, ruling, writ, quasi-judicial decision or award or
administrative decision or award of any federal, state, local, foreign or other court, arbitrator, tribunal, administrative agency or Governmental Entity to which any Person is a party or that is or may be binding on any Person or its securities,
assets or business. 
 9.16 “Person” means an association, a corporation, an individual, a partnership, a trust or
any other entity or organization, including a Governmental Entity. 
 9.17 “Products” means any product, component
or material the manufacture, use, importation, offer for sale or sale of which would infringe a Valid Claim in the country for which the Product is manufactured, used, imported, offered for sale or sold, where “Valid Claim” means a
claim of an issued and 

  
 19 

 
unexpired patent included within the Transferred Intellectual Property Rights, which has not been held unenforceable, unpatentable or invalid by an unappealed or unappealable order of a court or
other governmental agency of competent jurisdiction, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

9.18 “Purchased Contracts” means (a) the Assumed Contracts and (b) any Transferred Intellectual Property
Rights to the extent treated as executory contracts or unexpired leases under Section 365 of the Bankruptcy Code. 
 9.19
“Tax” means any federal, state, local or foreign income, gross receipts, property, sales, use, license, excise, employment, payroll, withholding or minimum tax, or any other tax, custom, duty, governmental fee or other like
assessment or charge of any kind whatsoever. 
 ARTICLE X 

MISCELLANEOUS 
 10.1
Amendments; Waivers. This Agreement and any schedule attached hereto may be amended only by agreement in writing of Buyer and Sellers. 

10.2 Governing Law. This Agreement and the legal relations between the parties shall be governed by and construed in accordance
with the laws of the State of Texas applicable to contracts made and performed in such State and without regard to conflicts of law doctrines, except to the extent that certain matters are preempted by federal law or are governed by the law of the
jurisdiction of incorporation or formation of the respective parties. 
 10.3 Assignment. The parties acknowledge and agree
that prior to the Closing, Buyer intends to transfer and assign all of its rights and obligations under this Agreement to the Buyer Transferee in accordance with Section 1.2(c) hereof. No assignment of the rights and obligations under
this Agreement or of all or any material portion of the Assets shall be effective unless and until the Buyer Transferee and any subsequent transferees agree in writing in substantially the form attached hereto as Exhibit A to assume all
obligations of the Buyer, or Buyer Transferee, if applicable, under this Agreement and to be bound by this Agreement and the obligations contained herein as if it had been a party hereto (as Buyer) on the date hereof, including without limitation,
the obligation to pay Contingent Royalty Payments resulting from Net Sales. Notwithstanding anything to the contrary in this Section 10.3, after such time as the maximum aggregate Contingent Royalty Payment of $30,000,000 has come due
and been paid to Sellers, any assignment of the rights and obligations under this Agreement or of all or any material portion of the Assets by Buyer, Buyer Transferee or any subsequent transferee will not be subject to the requirements of this
Section 10.3. 
 10.4 Expenses. Except as otherwise specifically provided in this Agreement, each party shall pay
its own expenses incident to the negotiation, preparation and performance of this Agreement and the transactions contemplated hereby, except that Sellers shall pay all costs of securing third-party consents and Approvals with respect to transfers of
the Assets or the Assumed Liabilities. 
 10.5 Parties in Interest. This Agreement shall be binding upon and inure to the
benefit of each party, and nothing in this Agreement, express or implied, is intended to confer upon any other person any rights or remedies of any nature whatsoever under or by reason of this Agreement. Nothing in this Agreement is intended to
relieve or discharge the obligation of any third person to, or to confer any right of subrogation or action over against, any party to this Agreement. The liquidating trust under the plan of reorganization of Sellers in the Bankruptcy Case (the
“Liquidating Trust”) shall be a third party beneficiary of this Agreement and may enforce all rights of Sellers under this Agreement. 

  
 20 

 10.6 Notices. Any notice, consent, waiver and other communication hereunder must be
in writing and shall be deemed to be duly given when (a) delivered in person, (b) transmitted by confirmed telefax or facsimile or (c) received if sent mailed by certified or registered mail, postage prepaid, return receipt requested,
as follows: 
 If to Sellers, addressed to: 

Introgen Therapeutics, Inc. 

Attn: Mike Ciesla, CRO 
 c/o
Munsch Hardt Kopf & Harr, P.C. 
 600 Congress Avenue, Suite 2900 

Telecopy: (512) 391-6100 

With copy to: 
 Munsch
Hardt Kopf & Harr, P.C. 
 600 Congress Avenue, Suite 2900 

Telecopy: (512) 391-6100 

Attention: Patricia Baron Tomasco, Esq. 

If to Buyer, addressed to: 

Pope Asset Management, LLC 

5100 Poplar Avenue, Suite 805 

Memphis TN 38137 
 Attention:
William Wells 
 Phone: +1 (901) 763-4001 

Fax: +1 (901) 763-4229 

With copy to: 
 Baker
Botts L.L.P. 
 1500 San Jacinto Center 

98 San Jacinto Boulevard 

Telecopy: (512) 322-8377 

Attention: Laura L. Tyson 
 or to such other
address or to such other person as either party shall have last designated by such notice to the other party. 
 10.7
Severability. If any provision of this Agreement is determined to be invalid, illegal or unenforceable by any court of competent jurisdiction or other Governmental Entity, such provision shall be fully severable and the remaining
provisions of this Agreement shall remain in full force and effect 
 10.8 Headings. The descriptive headings of the articles,
sections and subsections of this Agreement are for convenience only and do not constitute a part of this Agreement. 
 10.9
Counterparts. This Agreement and any amendment hereto or any other agreement (or document) delivered pursuant hereto may be executed in one or more counterparts and by different parties in separate counterparts. All of such
counterparts shall constitute one and the same agreement (or other 

  
 21 

 
document) and shall become effective (unless otherwise therein provided) when one or more counterparts have been signed by each party and delivered to the other party. Facsimile, pdf, or other
electronically delivered signatures shall constitute original signatures for all purposes of this Agreement. 
 10.10 Entire Agreement
and Modification. This Agreement supersedes all prior agreements between the parties with respect to its subject matter and constitutes (along with Transaction Documents) a complete and exclusive statement of the terms of the agreement
between the parties with respect to its subject matter. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 22 

 IN WITNESS WHEREOF, Sellers and Buyer have caused this Agreement to be duly executed on
its behalf as of the date first above written. 
  

			
	SELLERS
	
	INTROGEN THERAPEUTICS, INC.
		
	By:	 	 /s/ Michael L. Ciesla

		
	Name:	 	 Michael L. Ciesla

		
	Title:	 	 Chief Restructuring Officer

	
	INTROGEN TECHNICAL SERVICES, INC.
		
	By:	 	 /s/ Michael L. Ciesla

		
	Name:	 	 Michael L. Ciesla

		
	Title:	 	 Chief Restructuring Officer

	
	BUYER
	
	POPE INVESTMENTS II LLC
		
	By:	 	 /s/ William P. Wells

		
	Name:	 	 William P. Wells

		
	Title:	 	  

 SCHEDULES: 
  

			
	Schedule 1.1(a)(1)	  	Transferred Intellectual Property Assets
		
	Schedule 1.1(a)(2)	  	Assumed Contracts
		
	Schedule 1.1(a)(3)	  	Transferred Personal Property
		
	Schedule 1.1(a)(5)	  	Programs
		
	Schedule 2.1(a)(1)	  	Columbia Modification and Assignment Option Agreement
		
	Schedule 3.2(e)	  	Vivante Transferred Assets
		
	Schedule 6.6(a)	  	Patent Costs

 EXHIBITS: 
  

			
	Exhibit A	  	Joinder Agreement

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	716364	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	2/24/2000	 	Combined Therapeutical Treatment Of Hyperproliferative Disease	 	B. Tocque
									
	EP0800399	 	Belgium	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Switzerland	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Germany	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Denmark	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Spain	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	France	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Great Britain	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Greece	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Ireland	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Italy	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Liechtenstein	 	Aventis Pharma S.A..	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Luxembourg	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP0800399	 	Netherlands	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Portugal	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Sweden	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	213015	 	Mexico	 	Aventis Pharma S.A.S.A	 	PAT	 	1/17/1995	 	1/12/1996	 	2/25/2003	 		 	B. Tocque
									
	283989	 	Slovakia	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	7/712004	 		 	B. Tocquc
									
	6262032	 	United States	 	Aventis Pharma S.A.	 	PAT	 	7/17/1997	 	7/17/1997	 	7/17/2001	 		 	B. Tocque
									
	10/412,684	 	United States	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	4/14/2003	 		 		 	B. Tocque
									
	6485958	 	United States	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	12/16/1998	 	11/26/2002	 	Method For Producing Recombinant Adenovirus	 	F. Blanche; J.M. Guillaume
									
	778287	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	1/8/1998	 	11/25/2004	 		 	F. Blanche; Guillaume
									
	2004201075	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	7/25/2001	 	5/26/2005	 		 	F. Blanche; Guillaume
									
	EP0944717	 	Europe	 	Aventis Pharma S.A.	 	PAT	 	7/1/1996	 	6/20/1997	 		 		 	F. Blanche; Guillaume
									
	HU224558	 	Hungary	 	Aventis Pharma S.A.	 	PAT	 	7/1/1996	 	1/8/1998	 	10/28/2005	 		 	F. Blanche; Guillaume

  
 2 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6905862	 	United States	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	10/10/2002	 	6/14/2005	 		 	F. Blanche; Guillaume
									
	6537793	 	United States	 	Aventis Pharma S.A.	 	PAT	 	2/12/1999	 	6/14/2001	 	3/25/2003	 	Method Of Separating Viral Particles	 	F. Blanche; A. Barbot; Cameron
									
	779267	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	2/12/1999	 	7/13/2000	 	1/13/2005	 		 	F. Blanche; A. Barbot; Cameron
									
	EP1141249	 	Europe	 	Aventis Pharma S.A.	 	APP	 	12/13/1998	 	12/30/1999	 		 		 	F. Blanche; A. Barbot; Cameron
									
	696245	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	9/3/1998	 	Defective Recombinant Adenovirus For Gene ‘Therapy Of Tumors	 	Perricaudet; Haddada; E. May
									
	BR1101131	 	Brazil	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	11/4/1997	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Austria	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Belgium	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Switzerland	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E May
									
	EP0695360	 	Germany	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Denmark	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E, May
									
	EP0695360	 	Spain	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E May

  
 3 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP0695360	 	France	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Great Britain	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Greece	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Ireland	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Italy	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Liechtenstein	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Luxembourg	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Netherlands	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Portugal	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Sweden	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	220346	 	Hungary	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	8/28/1996	 		 	Perricaudet; Haddada; E. May
									
	8508879	 	Japan	 	Aventis Pharma S.A.	 	APP	 	4/22/1993	 	4/15/1994	 		 		 	Perricaudet; Haddada; E. May

  
 4 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	NO321454B	 	Norway	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	5/15/2006	 		 	Perricaudet; Haddada; E. May
									
	265306	 	New Zealand	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	10/24/1997	 		 	Perricaudet; Haddada; E. May
									
	7163925	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/17/1995	 	5/19/1998	 	1/16/2007	 	P16 Expression Constructs And Their APP In Cancer Therapy	 	X. Jin; J. Roth
									
	6251871B1	 	United States	 	The Board Regents of the University of Texas System	 	PAT	 	7/17/1995	 	2/16/1999	 	6/26/2001	 	P16 Constructs And Their App In Cancer Therapy	 	X. Jin; J. Roth
									
	5229109	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/14/1992	 	7/20/1993	 	Low Toxicity Interleukin-2 Analogues For Use In Immunotherapy	 	E. Grimm; K. Heaton
									
	FP0673257	 	Denmark	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/13/1993	 	10/16/2002	 		 	E. Grimm; K. Heaton
									
	EP0673257	 	Italy	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/13/1993	 	10/16/2002	 		 	E. Grimm; K. Heaton
									
	EP0673257	 	Liechtenstein	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/13/1993	 	10/16/2002	 		 	E. Grimm; K. Heaton

  
 5 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6899870	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/11/1998	 	3/11/1999	 	5/31/2005	 	Induction Of Apoptotic Or Cytotoxic Gene Expression By Adenoviral Mediated Gene Codelivery	 	T. McDonnell; S. Swisher; B. Fang; E. Bruckheimer; M. Sarkiss; L. Ji; J. Roth
									
	762493	 	Australia	 	The Board of Regents of The University of Texas System	 	PAT	 	3/11/1998	 	3/11/1999	 	10/9/2003	 		 	T. McDonnell; S. Swisher; B. Fang; E. Bruckheimer; M. Sarkiss; L. Ji; J. Roth
									
	2379171	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	1/15/2002	 		 	Methods For Treatment Of Hyperproliferative Diseases Using Human Mda-7	 	A. Mhashilkar, B. Schrok; S. Chada
									
	EP1307234	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	5/13/2000	 		 		 	A. Mhashilkar, B. Schrok; S. Chada
									
	EP200600226 61	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	10/30/2006	 		 		 	A. Mhashilkar, B. Schrok; S. Chada
									
	09/615,154	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	7/13/2000	 		 		 	A. Mhashilkar, B. Schrok; S. Chada
									
	EP1325125	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	7/10/2000	 	7/10/2001	 		 		 	L. Ji: J. Minna; J. Roth; M. Lerman
									
	10/445,718	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	7/10/2000	 	5/27/2003	 		 		 	L. Ji: J. Minna; J. Roth; M. Lerman
									
	2429769	 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	5/27/2003	 		 	Methods Of Treatment Involving Human Mda-7	 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh

  
 6 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1404359	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	12/7/2001	 		 		 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh
									
	10/017,472	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	12/7/2001	 		 		 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh
									
	11/746,531	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	8/30/2007	 		 		 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh
									
	2477780	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	8/31/2004	 		 	Methods Of Enhancing Immune Induction Involving Mda-7	 	Chada; Grimm; Mhashilkar; Ramesh
									
	03809886.5	 	China	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	3/3/2003	 		 		 	Chada; Pataer; Mhashilkar; Ramesh; Roth; Swisher;
									
	EP1490101	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	3/3/2003	 		 	-7	 	S. Chada; A. Pataer; A, Mhashilkar; R. Ramesh; J. Roth; S. Swisher;
									
	2003-574225	 	Japan,	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	11/2/2004	 		 		 	S. Chada; A. Pataer; A. Mhashilkar; R. Ramesh; J. Roth; S. Swisher;
									
	10/378,590	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	3/3/2003	 		 		 	S. Chada; A. Pataer; A. Mhashilkar; R. Ramesh; J. Roth; S. Swisher;
									
	11/000,341	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	12/30/2003	 	11/30/2004	 		 	Methods And Compositions To For Improved Non- Viral Gene Therapy	 	R. Ramesh; B. Gopalan; J. Roth

  
 7 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	2006-533032	 	Japan	 	Introgen Therapeutics. Inc.	 	APP	 	5/15/2003	 	5/14/2004	 		 		 	S. Zhang; H. Pham
									
	EP1603943	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	3/3/2003	 	3/2/2004	 		 		 	S. Chada; J. Mumm; R. Ramesh; A. Mhashilkar; Meyn; E. Grimm
									
	10/791,692	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	3/3/2003	 	3/2/2004	 		 		 	R. Chada; J. Mumm; R. Ramesh; A. Mhashilkar; R. Meyn; E. Grimm
									
	780613	 	Australia	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	8/4/2005	 	Replication-Competent Anti-Cancer Vectors	 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	2378586	 	Canada	 	St. Louis University	 	APP	 	7/12/1999	 	7/12/2000	 		 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Belgium	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Switzerland	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Germany	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Spain	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	France	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Great Britain	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson

  
 8 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1196616	 	Italy	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A, Tollefson
									
	2001-509486	 	Japan	 	St. Louis University	 	APP	 	7/12/1999	 	1/11/2002	 		 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	09/351,778	 	United States	 	St. Louis University	 	APP	 	7/12/1999	 	7/12/1999	 		 		 	W. Wald; K. Toth; K. Doronin; A. Tollefson
									
	11/249,873	 	United States	 	St. Louis University	 	APP	 	7/12/1999	 	10/13/2005	 		 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	2,548,220	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	12/1/2003	 	12/1/2004	 		 	Use Of Mda-7 To Inhibit Pathogenic Infectious Organisms	 	S. Chada
									
	11/001,702	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	12/1/2003	 	12/1/2004	 		 		 	S. Chada
									
	11/568,499	 	United States	 	St. Louis University	 	APP	 	4/30/2004	 	10/30/2006	 		 	Oncolytic Adenovirus Armed With Therapeutic Genes	 	S. Chada; W. Wold; L. Zumstein
									
	11/057,710	 	United States	 	St. Louis University	 	APP	 	12/2/2004	 	2/14/2005	 		 	Models For Viral Based Cancer Therapy	 	W. Wold; K. Toth; M. Thomas
									
	To Be Assigned	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	12/22/2004	 	12/22/2005	 		 	Use Of Flexible Bag Container For Viral Production	 	J. Senesac
									
	EP1758615	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	6/11/2004	 	6/29/2005	 		 	Combination Treatment Of Cancer With Elicitor Of Gene Product Expression And Gene-Product Targeting Agent	 	J. Roth; G. Schumacher; S. Chada
									
	11/150,521	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	6/11/2004	 	6/10/2005	 		 		 	J. Roth; G. Schumacher; S. Chada
									
	06770317.3	 	Europe	 	University of South Florida	 		 		 		 		 	P53 Vaccine For The Treatment Of Cancers	 	S. Antonia; D. Gabrilovich; S. Chada; K. Menander

  
 9 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	11/433,079	 	United States	 	University of South Florida	 	APP	 	5/12/2005	 	5/12/2006	 		 		 	S. Antonia; D. Gabrilovich; S. Chada; K.
									
	PCT/US 06/18 592	 	World	 	University of South Florida	 	PCT	 	5/12/2005	 	5/12/2006	 		 		 	S. Antonia D.; Gabrilovich; S. Chada; K. Menander
									
	2006206267	 	Australia	 	Introgen Therapeutics, Inc.	 	APP	 	1/2112005	 	1/20/2006	 		 	Topical Administration Permitting Prolonged Exposure Of Target Cells To Therapeutic And Prophylactic Viral Vectors	 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Canada	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	China	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Europe	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 	6/29/1905	 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	India	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Japan	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Korea	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang

  
 10 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	New Zealand	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Russia	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
	11/336,664	 	United States	 	Introgen Therapeutics Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Canada	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
		 	China	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
		 	India	 	The Board of Regents of the University of Texas System and Introgen Therapeutics. Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt

  
 11 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Japan	 	The Board of Regents of the University of Texas System and Introgen Therapeutics. Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
		 	Russia	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
	11/349,727	 	United States	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
	EP1827487	 	Europe	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc	 	APP	 	11/17/2004	 		 	2007	 	Cancer Immunotherapy Incorporating P53	 	M. Cristofanilli; S. Krishnamurthy; K. Menander; G. Hortobagyi
									
	11/281,922	 	United States	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc	 	APP	 	11/17/2004	 	11/17/2005	 		 		 	M. Cristofanilli; S. Krishnamurthy; K. Menander; G. Hortobagyi
									
	11/559,227	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	11/12/2005	 	11/13/2006	 		 	Methods for the Production and Purification of Adenoviral Vectors	 	S. Zhang,; H. Pham; P. Clarke

  
 12 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	PCT/US06/08 0847	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	11/12/2005	 	11/13/2006	 		 		 	S. Zhang; H. Pham; P. Clarke
									
	11/668,981	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	1/30/2006	 	1/30/2007	 		 	Prognostic Factors For Anti-Hyperproliferative Disease Gene Therapy	 	R Sobol; S. Chada; L. Zumstein; E. Cvitkovic; K. Menander
									
	PCT/US07/06 1320	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	1/30/2006	 	1/30/2007	 		 		 	R. Sobol; S. Chada; L. Zumstein; E. Cvitkovic; K. Menander
									
	11/748,826	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	5/15/2006	 	5/15/2007	 		 	Methods And Compositions For Protein Production Using Adenoviral Vectors	 	S. Zhang; H. Pham; P. Song; M. Zheng; P. Clarke
									
	PCT/US07/06 8977	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	5/15/2006	 	5/15/2007	 		 		 	S. Zhang; H. Pham; P. Song; M. Zheng; P. Clarke
									
	11/672,896	 	United States	 	The Board of Regents of The University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2006	 	2/8/2007	 		 	Compositions and Methods Involving Gene Therapy and Proteasome Modulation	 	R. Ramesh; S. Chada
									
	PCT/US07/06 1883	 	World	 	The Board of Regents of The University of Texas System and Introgen Therapeutics, Inc.	 	PCT	 	2/8/2006	 	2/8/2007	 		 		 	R. Ramesh; S. Chada
									
	11/764,719	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	6/16/2006	 	6/16/2007	 		 	Compositions And Methods Related To Adenovirus Based Delivery Of Antigens	 	P. Clarke
									
	PCT/US07/07 1490	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	6/16/2006	 	6/16/2007	 		 		 	P. Clarke

  
 13 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	11/741,594	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	4/28/2006	 	4/27/2007	 		 	Compositions and Methods Involving MDA-7 for the Treatment of Cancer	 	R. Ramesh
									
	PCT/US07/06 7691	 	World	 	The Board of Regents of The University of Texas System	 	PCT	 	4/28/2006	 	4/28/2007	 		 		 	R. Ramesh
									
		 	Australia	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 	Bioactive Fus1 Peptides and Nanoparticle-Polypeptide Complexes	 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	3/14/2005	 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	China	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	India	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth

  
 14 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Russia	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
	11/375,544	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	3/14/2005	 	3/14/2006	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
	PCT/US2008/055507	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	3/1/2007	 	2/29/2008	 		 		 	S. Zhang and E. Onishi
									
		 	Australia	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 	Methods And Composition Related To In Vivo Imaging Of Gene Expression	 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Canada	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B, Fang; L. Ji; D. Yang
									
		 	China	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang

  
 15 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Europe	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; 13. Fang; L. Ji; D. Yang
									
		 	India	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Japan	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Korea	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Russia	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kendra; B. Fang; L. Ji; D. Yang
									
	11/909,073	 	United States	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kendra; B. Fang; L. Ji; D. Yang
									
	6017524	 	United States	 	The Board of Regents of The University of Texas System; NIH	 	PAT	 	3/6/1991	 	10/13/1992	 	1/25/2000	 	Methods And Compositions For Retroviral Vector Mediated Transduction	 	J. Roth; T. Mukhopadyay; M. Tainsky

  
 16 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6,998,117	 	United States	 	The Board of Regents of The University of Texas System; NIH	 	PAT	 	3/6/1991	 	6/2/1995	 	2/14/2006	 		 	J. Roth; T. Mukhopadyay; M. Tainsky
									
	6436700	 	United States	 	The Board of Regents of the University of Texas System	 	PAT	 	3/6/1991	 	12/7/1992	 	8/20/2002	 	Anti-Sense K-Ras	 	J. Roth; T. Mukhopadhyay; M. Tainsky
									
	6410010	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/29/1993	 	6/25/2002	 	Recombinant p53 adenovirus methods and compositions	 	W. Zhang; J. Roth
									
	698437	 	Australia	 	The Board of Regents of the University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	2/11/1999	 		 	W. Zhang; J. Roth
									
	P19408179-4	 	Brazil	 	The Board of Regents of the University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	2174556	 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	ZL94194354.2	 	China	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	2/27/2002	 		 	W. Zhang; J. Roth

  
 17 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	288790	 	Czech Republic	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	7/4/2001	 		 	W. Zhang; J. Roth
									
	EP0725791	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	222981	 	Hungary	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	4/5/2004	 		 	W. Zhang; J. Roth
									
	JP 2003265193	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	10-1996-0702193	 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	10-2005-7005235	 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	275356	 	New Zealand	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	4/15/1998	 		 	W. Zhang; J. Roth

  
 18 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	186151	 	Poland	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	3/23/2004	 		 	W. Zhang; J. Roth
									
	2222600	 	Russia	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	3/23/2004	 		 	W. Zhang; J. Roth
									
	2222600	 	Russia	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	3/23/2004	 		 	W. Zhang; J. Roth
									
	PP509-96	 	Slovakia	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	73265	 	Ukraine	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	7/15/2005	 		 	W. Zhang; J. Roth
									
	6905873	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	4/2/1996	 	6/14/2005	 		 	W. Zhang; J. Roth
									
	6511847	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	9/21/2000	 	1/28/2003	 		 	W. Zhang; J. Roth

  
 19 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6830749	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	6/25/2002	 	12/14/2004	 		 	W. Zhang; J. Roth
									
	11/251,111	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/14/2005	 		 		 	W. Zhang; J. Roth
									
	7033750	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	6/11/2002	 	4/25/2006	 		 	W. Zhang; J. Roth
									
	EP0754237	 	Europe	 	The Board of Regents of the University of Texas System	 	APP	 	4/4/1994	 	4/4/1995	 		 	An adenovirus supervector system	 	W. Zhang; J. Roth
									
	7,252,989	 	United States	 	The Board of Regents of the University of Texas System	 	PAT	 	4/4/1994	 	4/4/1994	 	8/7/2007	 		 	W. Zhang; J. Roth
									
	6143290	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/29/1993	 	4/7/1994	 	11/7/2000	 	Tumor regression by adenovirus expression of wild-type p53	 	W. Zhang; J. Roth
									
	5747469	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/6/1991	 	4/25/1994	 	5/5/1998	 	Methods and compositions comprising DNA damaging agents and p53	 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub

  
 20 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Brazil	 	The Board of Regents of The University of Texas System	 	APP	 	3/6/1991	 	4/24/1995	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	695 35 684.4-08	 	Germany	 	The Board of Regents of The University of Texas System	 		 	3/6/1991	 	1/9/2008	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	JP 2003277272	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	3/6/1991	 	4/24/1995	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	1996 4527	 	Norway	 	The Board of Regents of The University of Texas System	 	APP	 	3/6/1991	 	4/24/1995	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	6627189	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/6/1991	 	7/17/1995	 	9/30/2003	 	Inhibition Of Cellular Proliferation Using Ras Antisense Molecules	 	J. Roth; T. Mukhopadhyay; M. Tainsky
									
	6740320	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	6/2/1995	 	6/2/1995	 	5/24/2004	 	Recombinant p53 adenovirus methods and compositions	 	W. Zhang; J. Roth
									
	6482803	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	9/1/1995	 	9/1/1995	 	11/19/2002	 	Modification of mutated p53 gene in tumors by retroviral delivery of ribozyme A	 	J. Roth; D. Cai; T. Mukhopadhyay

  
 21 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	5958892	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/30/1996	 	7/30/1996	 	9/28/1999	 	2-methoxyestradiol-induced apoptosis in cancer cells	 	T. Mukhopadhyay; J. Roth
									
	10-508981	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	7/30/1996	 	7/24/1997	 		 		 	T. Mulchopadhyay; J. Roth
									
	6133416	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	8/23/1996	 	8/22/1997	 	10/17/2000	 	Inhibition of cell growth by an anti-proliferative factor	 	D. Wilson; M. Lapadat-Tapolsky; T. Timmons, J. Lee; B. Almond; J. Roth
									
	6054467	 	United States	 	Introgen Therapeutics, Inc.	 	PAT	 	7/5/1996	 	7/5/1996	 	4/25/2000	 	Down-regulation of DNA repair to enhance sensitivity of p53 mediated suppression	 	R. Gjerset
									
	505400/1998	 	Japan	 	Introgen Therapeutics, Inc.	 	APP	 	7/5/1996	 	7/2/1997	 		 		 	R. Gjerset
									
	6110744	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	11/13/1996	 	11/12/1997	 	8/29/2000	 	Diminishing viral expression by promoter replacement	 	B. Fang; J. Roth
									
	6630344	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	11/13/1996	 	8/29/2000	 	10/7/2003	 		 	B. Fang; J. Roth
									
	7244671	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	11/13/1996	 	10/2/2003	 	7/17/2007	 		 	B. Fang; J. Roth

  
 22 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1724350	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	5/9/2006	 		 		 	G. Clayman
									
	3588048	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	11/27/1996	 		 		 	G. Clayman
									
	1998-0704074	 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	11/27/1996	 		 		 	G. Clayman
									
	P-327009	 	Poland	 	The Board of Regents of The University of Texas System	 	PAT	 	11/30/1995	 	11/27/1996	 	3/31/2003	 		 	G. Clayman
									
	08/758,033	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	11/27/1996	 		 		 	G. Clayman
									
	09/968,958	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	10/1/2001	 		 		 	G. Clayman
									
	11/200,527	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	8/9/2005	 		 		 	G. Clayman

  
 23 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	10/395,864	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	3/24/2003	 		 		 	G. Clayman
									
	6479285	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/2/1997	 	7/1/1998	 	11/12/2002	 	p53 as a regulator of cell differentiation	 	P. Vize; J. Wallingford
									
	6797702	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	4/25/1994	 	8/26/1997	 	9/28/2004	 	Methods and compositions comprising DNA damaging agents and p53	 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	7109179	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	4/25/1994	 	2/23/2004	 	9/19/2006	 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang: L. Owen-Schaub
									
	11/348,506	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	4/25/1994	 	2/6/2006	 		 	Grimm; T.	 	J. Roth; T. Fujiwara; E.A. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	6069134	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/6/1991	 	10/17/1997	 	5/30/2000	 	Methods and compositions comprising DNA damaging agents and p53	 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang: L. Owen-Schaub
									
	767880	 	Australia	 	Introgen Therapeutics, Inc.	 	PAT	 	3/16/1998	 	9/29/2000	 	3/11/2004	 	Multigene vectors	 	B. Almond; D. Wilson; S. Chada; L. Zumstein
									
	2323112	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	3/16/1998	 	9/14/2000	 		 		 	B. Almond; D. Wilson; S. Chada; L. Zumstein
									
	732703	 	Australia	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	11/20/1997	 	8/9/2001	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho

  
 24 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	2272820	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	97181254.3	 	China	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	523965/1998	 	Japan	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	503701	 	Korea	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	11/20/1997	 	7/18/2005	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	1999 2398	 	Norway	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	335497	 	New Zealand	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	11/20/1997	 	4/5/2001	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	2350890	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/16/1998	 	11/16/1999	 		 		 	Z. Wu; S. Zhang
									
	11/837,219	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	11/16/1998	 	8/10/2007	 		 		 	Z. Wu; S. Zhang
									
	11/837,269	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	11/16/1998	 	8/10/2007	 		 		 	Z. Wu; S. Zhang
									
	6429298	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1998	 	10/13/1999	 	8/6/2002	 	Assays for identifying functional alterations in the p53 tumor suppressor	 	A. Ellington; I. Matsumura
									
	09/422,911	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	10/21/1998	 	10/21/1999	 		 	Augmentation of cell growth inhibition by enhancement of intercellular communication	 	D. Frank; T. Liu; D. Wilson; G. Clayman

  
 25 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1165144	 	Europe	 	Vanderbilt University	 	APP	 	3/15/1999	 	3/15/2000	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	11/025,796	 	United States	 	Vanderbilt University	 	APP	 	3/15/1999	 	12/29/2004	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	11/269,112	 	United States	 	Vanderbilt University	 	APP	 	3/15/1999	 	11/8/2005	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	10/216,346	 	United States	 	Vanderbilt University	 	APP	 	3/15/1999	 	8/9/2002	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	775579	 	Australia	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	6/28/2001	 	11/18/2004	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho; S. Gallagher
									
	2353787	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	5/29/2001	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho; S. Gallagher
									
	09/575,473	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	5/24/1999	 	5/24/2000	 		 	Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases	 	R. Ramesh; J. Roth; T. Saeki; D. Wilson
									
	EP1754488	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	5/24/1999	 	5/9/2006	 		 		 	R. Ramesh; J. Roth; T. Saeki; D. Wilson
									
	6410029	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/30/1996	 	7/9/1999	 	6/25/2002	 	2-methoxyestradiol-induced apoptosis in cancer cells	 	T. Mukhopadhyay; J. Roth

  
 26 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6805858	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/6/1999	 	10/19/2004	 	Methods For The Administration Of Adenovirus P53	 	W. Zhang; J. Roth
									
	2002248341	 	Australia	 	The Board of Regents of The University of Texas System	 	PAT	 	1/11/2001	 	1/9/2002	 	2/26/2007	 	Antihelminthic drugs as a treatment for hyperproliferative diseases	 	T. Mukhopadhyay; J. Roth
									
	2434654	 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	1/11/2001	 	1/9/2002	 		 		 	T. Mukhopadhyay; J. Roth
									
	EP1425012	 	Europe	 	The Board of Regents of The University of Texas System	 	AP P	 	1/11/2001	 	1/9/2002	 		 		 	T. Mukhopadhyay; J. Roth
									
	10/043,877	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	1/11/2001	 	1/9/2002	 		 		 	T. Mukhopadhyay; J. Roth
									
	EP1496979	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	3/22/2002	 	3/24/2003	 		 		 	L. Ji; J. Roth
									
	11/746,531	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	3/22/2002	 	5/9/2007	 		 		 	L. Ji; J. Roth
									
	10/747,798	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	12/27/2002	 	12/29/2003	 		 	p53 treatment of papillomavirus and carcinogen transformed cells in hyperplastic leisions	 	G. Yoo

  
 27 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	5643761	 	United States	 	Columbia University	 	PAT	 	10/27/1993	 	10/27/1993	 	7/1/1997	 	Method for generating a subtracted eDNA library and uses of the generated library	 	P. Fisher; H. Jiang
									
	6720408	 	United States	 	Columbia University	 	PAT	 	10/27/1993	 	12/23/1998	 	4/13/2004	 		 	P. Fisher, H. Jiang
									
	10/417,827	 	United States	 	Columbia University	 	APP	 	10/27/1993	 	4/17/2003	 		 		 	P. Fisher; H. Jiang
									
	695540	 	Australia	 	Columbia University	 	PAT	 	10/27/1993	 	10/24/1994	 	11/26/1998	 		 	P. Fisher; H. Jiang
									
	2174354	 	Canada	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	98115996.5	 	Hong Kong	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	07-512754	 	Japan	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	702185/1996	 	Korea	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	5710137	 	United States	 	Columbia University	 	PAT	 	8/16/1996	 	8/16/1996	 	1/20/1998	 	Use of a melanoma differentiation associated gene (MDA-7) for inducing apoptosis of a tumor cell	 	P. Fisher
									
	6355622	 	United States	 	Columbia University	 	PAT	 	8/16/1996	 	2/16/1999	 	3/12/2002	 		 	P. Fisher
									
	6855686	 	United States	 	Columbia University	 	PAT	 	8/16/1996	 	11/21/2001	 	2/15/2005	 		 	P. Fisher
									
	727735	 	Australia	 	Columbia University	 	PAT	 	8/16/1996	 	8/15/1997	 	4/5/2001	 		 	P. Fisher

  
 28 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	2263750	 	Canada	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	97197914.6	 	China	 	Columbia University	 	PAT	 	8/16/1996	 	8/15/1997	 	9/15/2004	 		 	P. Fisher
									
	EP957941	 	Europe	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	510102/98	 	Japan	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	10-19999-7002342	 	Korea	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	991582	 	Mexico	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	334034	 	New Zealand	 	Columbia University	 	PAT	 	8/16/1996	 	2/3/1999	 	2/8/2001	 		 	P. Fisher
									
	2496918	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	8/28/2002	 	8/27/2003	 		 	Chromatographic methods for adenovirus purification	 	J. Senesac
									
	688839	 	Australia	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	7/2/1998	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	2177827	 	Canada	 	LXR Biotechnology, Inc.	 	APP	 	11/30/1993	 	5/30/1996	 		 		 	M, Kiefer; P. Barr
									
	EP0731636	 	Belgium	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr

  
 29 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP0731636	 	Germany	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Spain	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	France	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Great Britain	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Greece	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Ireland	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Italy	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer, P. Barr
									
	EP0731636	 	Luxembourg	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Monaco	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr

  
 30 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	F1962247	 	Finland	 	LXR Biotechnology, Inc.	 	APP	 	11/30/1993	 	11/30/1994	 		 		 	M. Kiefer; P. Barr
									
	NO962188	 	Norway	 	LXR Biotechnology, Inc.	 	APP	 	11/30/1993	 	11/30/1994	 		 		 	M. Kiefer; P. Barr
									
	6627190	 	United States	 	St. Louis University	 	PAT	 	7/12/1999	 	9/19/2001	 	9/30/2003	 	Recombinant adenovirus vectors that are replication competant in tert-expressing cells	 	W. Wold; K. Toth, K. Doronin; A. Tollefson; M. Kuppuswamy
									
	2005305347	 	Australia	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 	A novel method for the production and purification of adenoviral vectors	 	H. Pham; S. Zhang; P. Clarke
									
	2,586,107	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pham; S. Zhang; P. Clarke
									
	20058004233 4.4	 	China	 	Introgen Therapeutics, Inc..	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pham; S. Zhang; P. Clarke
									
	2007-540297	 	Japan	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pham; S. Zhang; P. Clarke
									
	10-2007-7012333	 	Korea	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pharr; S. Zhang; P. Clarke
									
	697088	 	Australia	 	Sidney Kimmel Cancer Center	 	PAT	 	4/29/1994	 	4/28/1995	 	9/24/1998	 	Enhancing the Sensitivity of Tumor Cells to Therapies	 	R. Gjerset; R. Sobol
									
	2189032	 	Canada	 	Sidney Kimmel Cancer Center	 	APP	 	4/29/1994	 	11/9/1995	 		 		 	R. Gjerset; R. Sobol
									
	9512554	 	Japan	 	Sidney Kimmel Cancer Center	 	APP	 	4/29/1994	 	4/28/1995	 		 		 	R. Gjerset; R. Sobol

  
 31 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	97702915	 	Korea	 	Sidney Kimmel Cancer Center	 	APP	 	4/29/1994	 	4/28/1995	 		 		 	R. Gjerset; R. Sobol
									
	6015687	 	United States	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	6/6/1995	 	1/18/2000	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	5998131	 	United States	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	10/10/1997	 	12/7/1999	 	Screening Methods For The Identification Of Compounds Capable Ofabrogating Bak-Bhrfi Protein Interactions	 	M. Kiefer; P. Barr
									
	6586395	 	United States	 	Tanox, Inc.	 	PAT	 	11/30/1993	 	6/6/1995	 	7/1/2003	 	Novel Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr
									
	7108989	 	United States	 	Tanox, Inc.	 	PAT	 	11/30/1993	 	3/1/2002	 	9/19/2006	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	6015687	 	United States	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	6/6/1995	 	6/23/1998	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	5770443	 	United States	 	LXR Biotechnology	 	PAT	 	11/30/1993	 	6/6/1995	 	6/23/1998	 		 	M. Kiefer; P. Barr
									
	6903195	 	United States	 	Tanox, Inc.	 	PAT	 	11/30/1993	 	8/7/2000	 	6/7/2005	 	Methods And Compositions For Detecting Cdn Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr
									
	11/082,485	 	United States	 	Tanox, Inc.	 	APP	 	11/30/1993	 	3/16/2005	 		 	Methods And Compositions For Detecting Cdn Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr
									
	1139871	 	China	 	LXR Biotechnology	 	APP	 	11/30/1993	 	11/30/1994	 		 	Novel Apoptosis-Modulating Proteins, Dna Encoding The Proteins And Methods Of Use Thereof	 	M. Kiefer; P. Barr
									
	9509567	 	Japan	 	Tanox, Inc	 	APP	 	11/30/1993	 	11/30/1994	 		 	Methods Of Screening For Therapeutic Agents Using M. Novel Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr

  
 32 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6413544	 	United States	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	10/4/1999	 	7/2/2002	 	Novel Liposomes For Increased Systemic Delivery	 	N. Smyth-Templeton; G. Pavlakis
									
	6770291	 	United States	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	11/2/2001	 	8/3/2004	 	Novel Liposomes For Increased Systemic Delivery	 	N. Smyth-Templeton; G. Pavlakis
									
	7,001,614	 	United States	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	4/15/2004	 	2/1/2006	 	Novel Liposomes For Increased Systemic Delivery	 	N. Smyth-Templeton; G. Pavlakis
									
	2263705	 	Canada	 	Department Of Health And Human Services	 	App	 	8/19/1996	 	8/1/1997	 		 	Novel Sandwich Liposome Complexes Comprising A Biologically Active Agent	 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Switzerland	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Germany	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	France	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Great Britain	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Italy	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis

  
 33 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	Ep0955999	 	Liechtenstein	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	 5/12/2001
	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Monaco	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Sweden	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	Nav N. Smyth-Templeton; G. Plakis
									
	730771	 	Australia	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	6/28/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	2000516630	 	Japan	 	Department Of Health And Human Services	 	App	 	8/19/1996	 	8/1/1997	 		 		 	N. Smyth-Templeton; G. Pavlakis

  
 34 

 Schedule 1.1(a)(2) Assumed Contracts 

Patent and Technology License Agreement between Introgen Therapeutics and the Board of Regents, dated July 20, 1994 (with all subsequent amendments,
schedules and attachments thereto) 
 Amended and Restated License Agreement between Introgen Therapeutics, Columbia University and Genquest, Inc. dated
July 18, 1997 
 Exclusive License Agreement between Corixa Corporation, Chinook Corporation and Introgen Therapeutics, Inc. dated July 19, 1999

 Milestone Extension Agreement between Trustees’s of Columbia University, Corixa Corporation and Introgen Therapeutics, Inc. dated August 12,
2001 
 Milestone Extension Agreement between Trustees’s of Columbia University, Corixa Corporation and Introgen Therapeutics, Inc. dated
August 12, 2001 
 Sponsored Research Agreement between Introgen Therapeutics and Oregon Health & Science University, dated September 31,
2007 
 Collaboration and License Agreement between Introgen Therapeutics and ViRx, dated March 7, 2002 

Research Agreement between Introgen Therapeutics and the Board of Regents for the University of Nebraska, dated October 1, 2007 

Patent License Agreement between Introgen Therapeutics and the National Institute of Health, dated September 22, 1998 

CRADA No. 02177 between Introgen Therapeutics and the National Institute of Health, dated March 22, 2007 

Clinical Investigation Agreement between Introgen Therapeutics and the University of Miami, dated May 5, 2000 

Patent License Agreement between Introgen and the University of Iowa Research Foundation, dated April 16, 1997 

 Schedule 1.1(a)(3) Transferred Personal Property Assets 

 

	1.	Advexin Vials: 

 MVB INVENTORY 
  

									
	 Description
	  	Lot No.	  	Part No.	  	Total No.
of Vials	 
	 Ad5CMV p53 MAG MVB I
	  	0048-0009	  	8.50013	  	 	5	  
	 Ad5CMV p53 INT MVB
	  	01698004
 001606
	  	08-00003
 08-00003
	  	 	36 39	  
	 Ad5CMV p53 INT WVB
	  	08198001	  	08-00004	  	 	697	  
	 Ad-MDA7 MVB
	  	MV241001	  	08-00049	  	 	7	  
	 INGN 007 (VRX-007) Virus Stock
	  	004710	  	08-00051	  	 	8	  
	 INGN 007 MVB
	  	MV007007	  	08-00052	  	 	93	  
	 INGN 201 WVB (Wave Process)
	  	WV201001	  	08-00059	  	 	200	  
		  		  		  	  
	  
	 
	 SUBTOTAL
	  		  		  	 	1,085	  
		  		  		  	  
	  
	 

 DP INVENTORY 
  

									
	 Description
	  	Lot No.	  	Part No.	  	Total No.
of Vials	 
	 INGN 201 (ADVEXIN)
	  	B1189801
B2159801
B1489901
B1839901
201-02-1-005	  	10-00007
10-00007
10-00007
10-00007
10-00007	  	 
 
 
 
 	147
538
16
693
108	  
  
  
  
  
	 Advexin (Ad5CMV-p53)- Quarantined, Consistency Batches
	  	P201004
P201005	  	10-00007
10-00007	  	 
  
	21
 86
	  
   

	 INGN 201 (WAVE Process)
	  	P201001	  	10-00032	  	 	1255	  
	 INGN 241
	  	P241001	  	10-00030	  	 	50	  
	 INGN 007
	  	P007007	  	10-00031	  	 	952	  
		  		  		  	  
	  
	 
	 SUBTOTAL
	  		  		  	 	3,866	  
		  		  		  	  
	  
	 
	 TOTAL
	  		  		  	 	4,951	  
		  		  		  	  
	  
	 

  

	2.	Support Data for Transferred Intellectual Property Rights, including all available: 

  

	 	a)	Clinical Data; 

  

	 	b)	Regulatory Data; and 

  

	 	c)	Radiological Scans and Unused Tissue Samples 

  

	 	d)	1 Terabyte external hard drive of documentation related to Transferred Intellectual Property 

 Schedule 1.1(a)(5) 

Programs are therapeutic products comprising nucleic acid constructs to express, promote or enhance expression of the following proteins or variants thereof:

 P53 
 MDA-7 

ADP Vectors comprising a DNA or a nucleotide construct, that expresses or promotes the expression of an E3 11.6K( protein or analog, homologue, variant
or derivative of such protein, and a viral vector that is replication competent in at least some cells, alone or in combination with other subject matter. It is understood that an ADP Vector may, in addition, include other subject matter, such as a
p53 gene or another gene construct. 
 It is understood the Programs include Advexin, INGN 225, INGN 241, INGN 007 and other products described above
including diagnostic, prognostic and predictive biomarkers of products’ efficacy and toxicity. 

 MODIFICATION AND ASSIGNMENT OPTION AGREEMENT 

COLUMBIA UNIVERSITY — INTROGEN THERAPEUTICS — POPE INVESTMENTS 

MDA — 7 GENE 
 This
Milestone Extension and Assignment Option Agreement (the “Agreement”) is dated as of             , 2009 (the “New Effective Date”) and will be effective as
of the later of (i) date the Bankruptcy Court enters a final order (“Order”) authorizing the assumption and assignment of the Exclusive License Agreement to Pope and (ii) upon Columbia’s receipt of the Cure Amount, and is by
and among: The Trustees of Columbia University in the City of New York, New York (“Columbia”); Introgen Therapeutics, 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (“Introgen”); and Pope Investments II LLC,
(“Pope Investments”). 
 WHEREAS, by the Exclusive License Agreement of July 19, 1999, as amended
August 8, 2000 and November 12, 2001 (collectively, the “Exclusive License Agreement”), Introgen is the exclusive licensee from Columbia of certain patents and technology relating to the use of the MDA-7 gene in treating disease;
and 
 WHEREAS, Columbia is successor in interest and assignee to all of the rights of Corixa Corporation and Chinook Corporation
under the Exclusive License Agreement; and 
 WHEREAS, Introgen desires to assign its entire interest and obligation as exclusive
licensee and any other interest and obligation under the Exclusive License Agreement to Pope Investments, which in turn will assign the Exclusive License Agreement rights to a new entity that is formed by Pope Investments in accordance with this
Agreement,(the “NEWCO”), and following such assignment, such NEWCO will succeed to all of Pope Investement interests and obligations under the Exclusive License Agreement; and 

WHEREAS, Columbia and Pope desire to amend the Exclusive License Agreement, as provided for herein, to extend the date for
accomplishing a certain milestone event pursuant to the Exclusive License Agreement; and 
 WHEREAS, Columbia and Pope Investment
desire to amend the Exclusive License Agreement, as provided for herein, regarding the transfer of technology to a Newco as further set forth below.; 

NOW, THEREFORE, it is agreed as follows: 

1. Extension of Date in Exclusive License Agreement. Paragraph 3.1(f) of the Exclusive License Agreement is amended to read as follows:

  

			
	 Event
	  	 Date of Accomplishment

		
	(f) Obtain FDA approval to market a vaccine or other therapeutic product in United States	  	On or before the fifth the anniversary of the New Effective Date

 2. Assignment to Pope Investments and Subsequent Sublicense to NEWCO. Introgen hereby
assigns its entire right, title and interest in and to the Exclusive License Agreement to Pope Investments. Columbia hereby consents to the foregoing assignment of the Exclusive License Agreement from Introgen to Pope Investments. Pope Investments
entire right, title and interest in and to the Exclusive License Agreement shall be subsequently sublicensed to NEWCO, as set forth below. Provided that the sublicense of the Exclusive License Agreement by Pope Investment to NEWCO is in accordance
with the terms of this Agreement, Columbia hereby consents to such sublicense. In addition, Pope Investment shall assign its rights, to the extent it is legally able to do so, to any and all intellectual property owned or controlled by Pope
Investment, as necessary or useful to support the development, manufacture and/or commercialization of either or both of the Licensed Technology and the Licensed Products, as such terms are defined in the Exclusive License Agreement (collectively
“Additional MDA-7 Rights”), to the NEWCO, as set forth below. The Exclusive License Agreement and the Additional MDA-7 Rights to be sublicensed and assigned, respectively, to NEWCO, shall be collectively referred to as the
“Technology.” 
  

	 	(a)	Creation of NEWCO. The parties agree to cooperate in the formation of a NEWCO in order to develop and commercialize the Technology in accordance with this Agreement, as follows: (1) Formation of NEWCO. Pope
Investments will form a new corporate entity to be the NEWCO hereunder, which formation shall be complete no later than sixty (60) days after Pope Investments have successfully concluded negotiations with Paul Fisher or another third party with
respect to development and commercialization of the Technology. The NEWCO’s initial capitalization will consist of founder’s shares held by Columbia equaling 15% of the outstanding common stock of the NEWCO. The remaining 85% of the
outstanding common stock of NEWCO shall be held by Pope Investments. The stock held by Columbia pursuant to this provision will be fully dilutable, founders-type shares and mirror the equity interest held by Pope Investments in the NEWCO at its
formation, and bear the same rights, preferences and privilege as the equity interest held by Pope Investments 

  

	 	(b)	Negotiations with Paul Fisher. Pope Investments will negotiate in good faith with Paul Fisher and his designees for the transfer of a portion of the 85% of the common stock in the Assignee, but Pope investments does not
make any guarantee that such equity interests will be granted. 

  

	 	(c)	NEWCO will enter into a mutually acceptable Development Plan with Columbia and Pope Investments in order to diligently develop and commercialize the Technology. 

3. Further Assurances. The parties agree (i) to furnish upon request to each other such further information, (ii) to execute
and deliver to each other such other documents, and (iii) to do such other acts and things, all as the other party may reasonably request for the purpose of carrying out the intent of this Agreement and the actions required by this Agreement.

 4. Injunctive Relief. The parties recognize and acknowledge that irreparable damage might result to Columbia or Pope Investments
if this Agreement is breached by the other party. In the event of any such breach and in addition to all other remedies to which Columbia or Pope Investments may be entitled, Columbia or Pope Investments shall be entitled to pursue immediate and
injunctive relief from any court of competent jurisdiction in connection with such breach, notwithstanding the arbitration procedures provided for in the Exclusive License Agreement 

  
 2 

 5. Payment to Columbia. In consideration of the foregoing, Introgen shall pay in full to
Columbia, within ten (10) days from the date the Cure Amount is determined, monies due and owing to Columbia by Introgen under the Exclusive License Agreement (the ‘Cure Amount). The Cure Amount shall be determined though the good faith
negotiations of Dr. Robert Sobol and Shai Gilad with reference to the terms of the Exclusive License Agreement and shall be limited to only those expenses due and owing to Columbia pursuant to the Exclusive License Agreement. Such Cure Amount
paid to Columbia shall be non-refundable. In the event the parties cannot reach a mutually agreeable Cure Amount determination, then parties shall submit to a hearing in front of the Bankruptcy Court on November 16, 2009 at 1:30pm. 

6. Retained Right. Columbia has the right, in the event of failure by Pope Investments or Introgen to comply with the terms and
conditions of this Agreement, to terminate the Exclusive License Agreement in accordance with the notice and cure terms of the Exclusive License Agreement. 

7. Governing Law. This Agreement shall be governed by the laws of the State of New York, without regard to its principles of conflicts
of laws, notwithstanding Section 13.7 of the Exclusive License Agreement, The Parties further agree to subject themselves to the personal jurisdiction of the federal and state courts of the State of New York. 

8. Validity. This Modification and Assignment Agreement shall not be valid or enforceable without both Bankruptcy Court approval and
Columbia’s receipt of Cure Amount in verified funds. 
 9. No Other Changes. Except as herein amended, the Exclusive License
Agreement shall continue in full force and effect in accordance with its terms. 
 IN WITNESS WHEREOF, the parties have caused this
Agreement to be executed by their duly authorized representatives as of the New Effective Date. 
  

			
	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	POPE INVESTMENTS II LLC
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	INTROGEN THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 3 

 Schedule 3.2(e) Vivante Transferred Assets 

1 Vial: HEK293 Master Cell Bank 004374 (part number 08-00047) 

3 Vials: HEK293 Working Cell Bank WC007001 (part number 08-00050) 

 Schedule 6.6—Patent Costs 

 

											
	 Docket No.
	  	 Title
	  	 Date
Filed
	  	 Application
No.
	  	Registration
No.	  	 Payment 
Due

						
	INRP:097U5D1	  	 Protamine Adenoviral Vector Complexes and Methods of Use
	  	5/09/07	  	11/746531	  		  	11/01/09: $130.00
						
	INRP:005USD2	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	6/11/02	  	10/170240	  	7033750	  	10/25/09: $1225.00
						
	INRP:005-AU	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	80949/94	  	698437	  	10/28/09: $1301.00
						
	INRP:005-CA	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	2174556	  	2174556	  	10/28/09: $890.00
						
	INRP:005-CN	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	94194354.2	  	94194354.2	  	10/28/09: $1638.00
						
	INRP:005-CZ	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	PV1225-96	  	288790	  	10/28/09: $1421.00
						
	INRP:005-HU	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	P9601084	  	222981	  	10/28/09: $1411.00
						
	INRP:005-PL	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	P314311	  	186151	  	10/28/09: $1243.00
						
	INRP:005-RU	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	96110223	  	2222600	  	10/28/09: $1120.00
						
	INRP:005-UA	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	96041651	  	73265	  	10/28/09: $1302.00
						
	INGN:168WO	  	 P53 Biomarkers
	  	01/26/09	  	PCT/US2009/032029	  		  	Deadline to file Chapter 11 demand is 10/29/09
						
	INRP:008-AU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	23924/95	  	694216	  	10/24/09: $1300.00
						
	INRP:008-BR	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	PI9507506.2	  		  	10/24/09: $1300.00
						
	INRP:008-BRD1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	PI9510797.5	  		  	10/24/09: $1300.00
						
	INRP:008-CN	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95192776.0	  	95192776	  	10/24/09: $2000.00
						
	INRP:008-CZ	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	PV3121/96	  	295144	  	10/24/09: $2000.00
						
	INRP:008-EAT	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $2300.00
						
	INRP:008-EAT1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	E383167	  	10/30/09: $2300.00
						
	INRP:008-EBE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.00	  	0760675	  	10/30/09: $1500.00
						
	INRP:008-EBE1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1500.00

  
 1 

											
	 Docket No.
	  	 Title
	  	 Date
Filed
	  	 Application
No.
	  	Registration
No.	  	 Payment 
Due

						
	INRP:008-ECH	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1300.00
						
	INRP:008-ECHL1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1300.00
						
	INRP:008-EDE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	69521994.4	  	10/30/09: $2700.00
						
	INRP:008-EES	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	2160707	  	10/30/09: $1600.00
						
	INRP:008-EES1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1600.00
						
	INRP:008-EFR	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	959171000.0	  	0760675	  	10/30/09: $1700.00
						
	INRP:008-EGB	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	959171000.0	  	0760675	  	10/30/09: $1500.00
						
	INRP:008-EIE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	959171000.0	  	0760675	  	10/30/09: $1600.00
						
	INRP:008-EIE1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1600.00
						
	INRP:008-EIT	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $2100.00
						
	INRP:008-EIT1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $2100.00
						
	INRP:008-ELU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1300.00
						
	INRP:008-ELU1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1300.00
						
	INRP:008-EMC	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1600.00
						
	INRP:008-EMC1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1600.00
						
	INRP:008-ENL	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $2500.00
						
	INRP:008-ENL1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $2500.00
						
	INRP:008-ESE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1600.00

  
 2 

											
	 Docket No.
	  	 Title
	  	 Date
Filed
	  	 Application
No.
	  	Registration
No.	  	 Payment 
Due

						
	INRP:008-ESE1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/24/09: $1600.00
						
	INRP:008-HU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	P9602937	  	221279	  	10/30/09: $2100.00
						
	INRP:008-PL	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	P-317105	  	185749	  	10/24/09: $1600.00
						
	INRP:008-RU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	96122787	  	2146149	  	10/24/09: $2000.00
						
	INRP:008-NO	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	19964527	  	325560	  	10/30/09: $1700.00
						
	INRP:005E-	  	 Recombinant p53 Adenovirus Methods and Compositions
	  	10/28/94	  	94932099.8	  		  	11/3/09: $600.00
						
	AO-INRP:008	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/94	  	08/233002	  	5747469	  	11/5/09: $4110.00
						
	INRP:083US	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	09/575473	  		  	11/12/09: $1730.00
						
	INGN:147US	  	 Compositions and Methods Involving Gene Therapy and Proteasome Modulation
	  	9/16/08	  	11/672896	  		  	11/18/09: $130.00
						
	INRP:083EBE	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1300.00
						
	INRP:083ECH	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00
						
	INRP:083EDE	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	60030970.3	  	11/30/09: $1500.00
						
	INRP:083EES	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00
						
	INRP:083EFR	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00
						
	INRP:083EGB	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1300.00
						
	INRP:083EIT	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	36672BE/20 06	  	11/30/09: $2000.00
						
	INRP:083ESE	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]